National Biofilms Innovation Centre
Lead Research Organisation:
University of Southampton
Department Name: Sch of Biological Sciences
Abstract
The University of Southampton will receive the award on behalf of the lead institutions of the NBIC consortium (University of Southampton, University of Liverpool, University of Nottingham and the University of Edinburgh). The University of Southampton will also be responsible for the disbursement of funds to the lead institutions of the NBIC consortium. The Grant Holder will be Jeremy Webb (Principle Investigator, Corresponding) on behalf of the NBIC Consortium lead investigators Jeremy Webb (Southampton), Rasmita Raval (Liverpool), Cait MacPhee (Edinburgh) and Miguel Camara (Nottingham)".
Biofilms are central to some of the most urgent global challenges and exert considerable economic impact across industry sectors. They are a leading cause of antimicrobial resistance (AMR), forecast to cost $100tn in world GDP and 10m deaths by 2050. Biofilms are the major cause of chronic infections, costing the NHS £2bn p.a. Contamination, energy losses and damage by biofilms impact on the £70bn UK foods industry, the $2.8 trillion consumer products sector, and $117bn global coatings industry. Biofilm management is essential to deliver clean and globally sustainable drinking water and food security.
The National Biofilms Innovation Centre (NBIC) will deliver a future where biofilms can be effectively controlled and harnessed, increasing value for the companies we work with, and providing pathways to impact for world-class research across the UK. NBIC will bring UK companies from across the industrial sectors around the table with the best of UK biofilm research to accelerate the adoption of new technologies into company products and services. Where companies are not ready to take an opportunity to market, we will provide world class entrepreneurial training to maximise the success of our spin outs
NBIC will provide a focus for industry partners to access biofilm research across the UK, simplifying knowledge transfer and catalysing collaboration. Working with industry, NBIC will produce sector roadmaps, identifying the unmet needs of the sectors, and the key scientific, commercial, technical and regulatory barriers to meet them. The roadmaps will provide a key context for the evolution of the NBIC science strategy.
NBIC will leverage existing investments in research, facilities and people to address near and long term industrial and societal challenges and to establish a pathway for the accelerated adoption of new biofilm innovations and technologies, whilst significantly promoting the expansion of a highly trained researcher workforce in this field.
We will develop the next generation of leaders in biofilms with bespoke scientific, entrepreneurial and leadership training, and we will undertake International exchanges of students and staff with SCELSE biofilms centre in Singapore. We will engage with all of the university doctoral colleges with a view to submitting a bid to the 2019 DTP call.
We will draw on the considerable outreach and engagement experience of the NBIC partners to share and develop tailored events and activities suitable for primary and secondary schools, CPD for teachers, science festivals, youth groups and community-based organisations throughout the UK.
Biofilms are central to some of the most urgent global challenges and exert considerable economic impact across industry sectors. They are a leading cause of antimicrobial resistance (AMR), forecast to cost $100tn in world GDP and 10m deaths by 2050. Biofilms are the major cause of chronic infections, costing the NHS £2bn p.a. Contamination, energy losses and damage by biofilms impact on the £70bn UK foods industry, the $2.8 trillion consumer products sector, and $117bn global coatings industry. Biofilm management is essential to deliver clean and globally sustainable drinking water and food security.
The National Biofilms Innovation Centre (NBIC) will deliver a future where biofilms can be effectively controlled and harnessed, increasing value for the companies we work with, and providing pathways to impact for world-class research across the UK. NBIC will bring UK companies from across the industrial sectors around the table with the best of UK biofilm research to accelerate the adoption of new technologies into company products and services. Where companies are not ready to take an opportunity to market, we will provide world class entrepreneurial training to maximise the success of our spin outs
NBIC will provide a focus for industry partners to access biofilm research across the UK, simplifying knowledge transfer and catalysing collaboration. Working with industry, NBIC will produce sector roadmaps, identifying the unmet needs of the sectors, and the key scientific, commercial, technical and regulatory barriers to meet them. The roadmaps will provide a key context for the evolution of the NBIC science strategy.
NBIC will leverage existing investments in research, facilities and people to address near and long term industrial and societal challenges and to establish a pathway for the accelerated adoption of new biofilm innovations and technologies, whilst significantly promoting the expansion of a highly trained researcher workforce in this field.
We will develop the next generation of leaders in biofilms with bespoke scientific, entrepreneurial and leadership training, and we will undertake International exchanges of students and staff with SCELSE biofilms centre in Singapore. We will engage with all of the university doctoral colleges with a view to submitting a bid to the 2019 DTP call.
We will draw on the considerable outreach and engagement experience of the NBIC partners to share and develop tailored events and activities suitable for primary and secondary schools, CPD for teachers, science festivals, youth groups and community-based organisations throughout the UK.
Technical Summary
Technical Summary
NBIC will work across 4 strategic themes to prevent, detect, manage and engineer biofilms, capitalising on world-class underpinning research to address sectoral challenges identified with our industry partners. NBIC will work with industry, regulators, funders and policymakers, and engage the public in a two-way dialogue to refine the research and industrial strategy agenda, shape public funding initiatives and determine strategy for industrial pre- and post-competitive research.
The strategy and remit of the 4 themes are as follows:
PREVENT: Prevention of early stage microbial adhesion and colonisation events at surfaces. Advanced techniques to create next-generation biofilm prevention strategies.
DETECT: Accurate, quantitative biofilm detection and metrology across multiple scales through innovative sensing, tracking and diagnostic technologies. Identify and exploit new and known biofilm-specific biomarkers.
MANAGE: To kill, remove or control established biofilms by understanding and exploiting their life cycle dynamics and development across a range of environments and levels of complexity.
ENGINEER: Harness the benefits of complex microbial consortia from knowledge of their composition, function, ecology and evolution. Exploit biofilm understanding at the interface with engineering and process applications.
CROSS-CUTTING THEME: PREDICTIVE MODELLING. This theme will exploit our expertise in computational and mathematical tools for understanding, modelling and simulating biological and physical processes and activities of biofilms.
By addressing the scientific challenges and strategy outlined above, NBIC will help companies create value by benefiting from biofilms or by addressing the challenges that they face caused by biofilms.
NBIC will work across 4 strategic themes to prevent, detect, manage and engineer biofilms, capitalising on world-class underpinning research to address sectoral challenges identified with our industry partners. NBIC will work with industry, regulators, funders and policymakers, and engage the public in a two-way dialogue to refine the research and industrial strategy agenda, shape public funding initiatives and determine strategy for industrial pre- and post-competitive research.
The strategy and remit of the 4 themes are as follows:
PREVENT: Prevention of early stage microbial adhesion and colonisation events at surfaces. Advanced techniques to create next-generation biofilm prevention strategies.
DETECT: Accurate, quantitative biofilm detection and metrology across multiple scales through innovative sensing, tracking and diagnostic technologies. Identify and exploit new and known biofilm-specific biomarkers.
MANAGE: To kill, remove or control established biofilms by understanding and exploiting their life cycle dynamics and development across a range of environments and levels of complexity.
ENGINEER: Harness the benefits of complex microbial consortia from knowledge of their composition, function, ecology and evolution. Exploit biofilm understanding at the interface with engineering and process applications.
CROSS-CUTTING THEME: PREDICTIVE MODELLING. This theme will exploit our expertise in computational and mathematical tools for understanding, modelling and simulating biological and physical processes and activities of biofilms.
By addressing the scientific challenges and strategy outlined above, NBIC will help companies create value by benefiting from biofilms or by addressing the challenges that they face caused by biofilms.
Planned Impact
Impact summary
The National Biofilms Innovation Centre will bring together academic researchers from multiple disciplines; facilitate existing academic/industry collaborations where relevant and appropriate; broker new interactions between the academic research base and industry; and draw upon world-class underpinning bioscience to address unmet industry needs. NBIC will create the world's premier centre for biofilms training and research, and ensure its translation into capacity building and innovation.
NBIC will engage with industry by facilitating knowledge integration and capacity building. NBIC will be a single point of call for companies with challenges that relate to biofilm technologies, whether the challenge is to prevent (e.g. in human health applications), detect (e.g. in potable water systems), manage (e.g. in wastewater treatment plants) or engineer (e.g. in industrial biotechnology applications). Given this wide field of potential sectors, NBIC will draw on and facilitate links with all relevant disciplines across the physical, life, medical and social sciences. The goal is bidirectional: to ensure the maximum impact of world-class underpinning science, as well as respond directly to unmet industry needs. NBIC will achieve this by: establishing sector-specific roadmaps to educate and influence the academic base; the allocation of joint academic/industry collaborative funding; provision of entrepreneurial training for early career researchers and established academics; and the organisation of multiple different types of events, all designed to enrich relationships between Universities and companies.
Market analysis indicates that the formation, control, removal or use of biofilm technology has a global impact on economic activity of $5,000bn. Fundamental scientific breakthroughs remain to be made, and the purpose of NBIC is to form a UK-wide collaborative community best able to make these breakthroughs, and ensure their translation into products, services, devices, materials and protocols that will benefit the general public.
By delivering a coherent national response to the challenges in biofilms research, NBIC will increase the efficiency and impact of the research across the UK for all the academics that work with it.
We will create value for the companies we work with by placing at the heart of our research strategy, solving their problems and helping them access new opportunities.
By providing companies and society with new tools to prevent, detect, manage and engineer biofilms we will significantly reduce the harm that they cause and improve clinical outcomes from persistent infections and biofilm related disease.
We will develop the next generation of leaders in biofilms with bespoke scientific, entrepreneurial and leadership training, and we will undertake International exchanges of students and staff with SCELSE biofilms centre in Singapore. We will engage with all of the university doctoral colleges with a view to submitting a bid to the 2019 BBSRC DTP call.
We will draw on the considerable outreach and engagement experience of the NBIC partners to share and develop tailored events and activities suitable for primary and secondary schools, CPD for teachers, science festivals, youth groups and community-based organisations throughout the UK.
The National Biofilms Innovation Centre will bring together academic researchers from multiple disciplines; facilitate existing academic/industry collaborations where relevant and appropriate; broker new interactions between the academic research base and industry; and draw upon world-class underpinning bioscience to address unmet industry needs. NBIC will create the world's premier centre for biofilms training and research, and ensure its translation into capacity building and innovation.
NBIC will engage with industry by facilitating knowledge integration and capacity building. NBIC will be a single point of call for companies with challenges that relate to biofilm technologies, whether the challenge is to prevent (e.g. in human health applications), detect (e.g. in potable water systems), manage (e.g. in wastewater treatment plants) or engineer (e.g. in industrial biotechnology applications). Given this wide field of potential sectors, NBIC will draw on and facilitate links with all relevant disciplines across the physical, life, medical and social sciences. The goal is bidirectional: to ensure the maximum impact of world-class underpinning science, as well as respond directly to unmet industry needs. NBIC will achieve this by: establishing sector-specific roadmaps to educate and influence the academic base; the allocation of joint academic/industry collaborative funding; provision of entrepreneurial training for early career researchers and established academics; and the organisation of multiple different types of events, all designed to enrich relationships between Universities and companies.
Market analysis indicates that the formation, control, removal or use of biofilm technology has a global impact on economic activity of $5,000bn. Fundamental scientific breakthroughs remain to be made, and the purpose of NBIC is to form a UK-wide collaborative community best able to make these breakthroughs, and ensure their translation into products, services, devices, materials and protocols that will benefit the general public.
By delivering a coherent national response to the challenges in biofilms research, NBIC will increase the efficiency and impact of the research across the UK for all the academics that work with it.
We will create value for the companies we work with by placing at the heart of our research strategy, solving their problems and helping them access new opportunities.
By providing companies and society with new tools to prevent, detect, manage and engineer biofilms we will significantly reduce the harm that they cause and improve clinical outcomes from persistent infections and biofilm related disease.
We will develop the next generation of leaders in biofilms with bespoke scientific, entrepreneurial and leadership training, and we will undertake International exchanges of students and staff with SCELSE biofilms centre in Singapore. We will engage with all of the university doctoral colleges with a view to submitting a bid to the 2019 BBSRC DTP call.
We will draw on the considerable outreach and engagement experience of the NBIC partners to share and develop tailored events and activities suitable for primary and secondary schools, CPD for teachers, science festivals, youth groups and community-based organisations throughout the UK.
Organisations
- University of Southampton (Lead Research Organisation)
- INNOVATE UK (Co-funder, Collaboration)
- Singapore Centre for Environmental Life Sciences Engineering (Collaboration)
- James Hutton Institute (Collaboration)
- Edinburgh Bioquarter (Collaboration)
- Victoria and Albert Museum (Collaboration)
- Chinese Scholarship Council (Collaboration)
- Intelligent Imaging Innovations Ltd (Collaboration)
- Magnitude Biosciences (Collaboration)
- Tecrea Ltd (Collaboration)
- UNIVERSITY OF BIRMINGHAM (Collaboration)
- Biotechnology and Biological Sciences Research Council (BBSRC) (Collaboration)
- Northumbrian Water (Collaboration)
- Aarhus University (Collaboration)
- University of Navarra (Collaboration)
- Lancaster University (Collaboration)
- Belfry Therapeutics (Collaboration)
- UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST (Collaboration)
- CHILLED FOOD ASSOCIATION (Collaboration)
- University of Hull (Collaboration)
- Montana State University (Collaboration)
- Commonwealth Scientific and Industrial Research Organisation (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Argent Energy (Collaboration)
- Tata Steel Europe (Collaboration)
- BRUNEL UNIVERSITY LONDON (Collaboration)
- National University of Río Cuarto (Collaboration)
- Science and Technologies Facilities Council (STFC) (Collaboration)
- High Value Manufacturing Catapult (Collaboration)
- SELLAFIELD LTD (Collaboration)
- UNIVERSITY OF DUNDEE (Collaboration)
- EARLHAM INSTITUTE (Collaboration)
- Eberhard Karls University of Tübingen (Collaboration)
- Veolia Environmental Trust (Collaboration)
- NANYANG TECHNOLOGICAL UNIVERSITY (Collaboration)
- Whittington Health NHS Trust (Collaboration)
- ShimyaTech Ltd (Collaboration)
- Virustatic Shield Ltd (Collaboration)
- PENTAX Medical Company (Collaboration)
- Smith and Nephew (Collaboration)
- University of Laval (Collaboration)
- Veolia Water Technologies (Collaboration)
- Seaweed and Co (Collaboration)
- FRONTIER IP GROUP PLC (Collaboration)
- Creo Medical Ltd (Collaboration)
- Knowledge Economy Skills Scholarships (KESS) (Collaboration)
- United Kingdom Research and Innovation (Collaboration)
- Novozymes (Collaboration)
- LGC Ltd (Collaboration)
- Welsh Wound Innovation Centre (Collaboration)
- UNIVERSITY OF LIVERPOOL (Collaboration)
- Makerere University (Collaboration)
- Quadram Institute Bioscience (Collaboration)
- Arm Limited (Collaboration)
- MANCHESTER UNIVERSITY NHS FOUNDATION TRUST (Collaboration)
- Kohler Co (Collaboration)
- Adaptavate (Collaboration)
- Scotland's Rural College (Collaboration)
- FOURTH STATE MEDICINE LTD (Collaboration)
- National Institute for Health Research (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- UNIVERSITY OF GHANA (Collaboration)
- Government of Saudi Arabia (Collaboration)
- CytaCoat (Collaboration)
- UNIVERSITY OF YORK (Collaboration)
- Edinburgh Napier University (Collaboration)
- Genesis Biosciences (Collaboration)
- Tripura University (Collaboration)
- Reta Lila Weston Trust For Medical Research (Collaboration)
- Regional Centre for Biotechnology (Collaboration)
- BAM Federal Institute for Materials Research and Testing (Collaboration)
- Karolinska Institute (Collaboration)
- University of Warwick (Collaboration)
- AlgiPharma (Collaboration)
- UNIVERSITY OF STRATHCLYDE (Collaboration)
- AkzoNobel (Collaboration)
- Kohler Mira Ltd (Collaboration)
- University of Bath (Collaboration)
- Yeo Marketing Limited (Collaboration)
- Heriot-Watt University (Collaboration)
- Croda International (Collaboration)
- BluTest Laboratories Limited (Collaboration)
- European Circuits Limited (Collaboration)
- Medicines Discovery Catapult (Collaboration)
- Britest (Collaboration)
- UNIVERSITY OF ESSEX (Collaboration)
- UNIVERSITY OF SOUTHAMPTON (Collaboration)
- UNIVERSITY OF LINCOLN (Collaboration)
- National Scientific and Technical Research Council (Argentina) (Collaboration)
- NIHR Southampton Biomedical Research Centre (Collaboration)
- Ceramisys (Collaboration)
- University of La Plata (Collaboration)
- Cica Biomedical Ltd (Collaboration)
- Rosetrees Trust (Collaboration)
- National University of Rosario (Collaboration)
- British Geological Survey (Collaboration)
- MANCHESTER METROPOLITAN UNIVERSITY (Collaboration)
- UNIVERSITY OF NEWCASTLE (Collaboration)
- Liverpool John Moores University (Collaboration)
- 5D HEALTH PROTECTION GROUP LTD (Collaboration)
- Scottish Water (United Kingdom) (Collaboration)
- SWANSEA UNIVERSITY (Collaboration)
- SALFORD ROYAL NHS FOUNDATION TRUST (Collaboration)
- UNIVERSITY OF BRADFORD (Collaboration)
- UNIVERSITY OF THE HIGHLANDS AND ISLANDS (Collaboration)
- Polytechnic University of Valencia (Collaboration)
- Plantwork Systems (PWS) Ltd (Collaboration)
- Jiangxi Normal University (Collaboration)
- Cystic Fibrosis Foundation (Collaboration)
- Mid Yorkshire Hospitals NHS Trust (Collaboration)
- Veolia Environmental Services (Collaboration)
- Mondelez International (Collaboration)
- ISLE OF WIGHT COUNCIL (Collaboration)
- CYSTIC FIBROSIS TRUST (Collaboration)
- Plantworks Ltd UK (Collaboration)
- Adtec Plasma Technology (Collaboration)
- Teleflex Medical (Collaboration)
- NOVA SA (Collaboration)
- DNV GL (Collaboration)
- University College London (Collaboration)
- CYANOFEED LTD (Collaboration)
- Environmental Monitoring Solutions Ltd (Collaboration)
- BARTS HEALTH NHS TRUST (Collaboration)
- OsteoCare Implant System Ltd (Collaboration)
- Shell Global Solutions International BV (Collaboration)
- Technical University of Denmark (Collaboration)
- Delft University of Technology (TU Delft) (Collaboration)
- Alderley Park (Collaboration)
- Perlemax (Collaboration)
- BIRMINGHAM CITY UNIVERSITY (Collaboration)
- CROMERIX LTD (Collaboration)
- Oxi-Tech Solutions Ltd (Collaboration)
- BP (British Petroleum) (Collaboration)
- LOUGHBOROUGH UNIVERSITY (Collaboration)
- Harman Technology (Collaboration)
- KEELE UNIVERSITY (Collaboration)
- Liverpool School of Tropical Medicine (Collaboration)
- University of Surrey (Collaboration)
- Karlsruhe Institute of Technology (Collaboration)
- Nottingham Trent University (Collaboration)
- Diamond Coatings Limited (Collaboration)
- Johns Hopkins University (Collaboration)
- Laboratory of the Government Chemist (LGC) Ltd (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- Royal HaskoningDHV (Collaboration)
- CAIRN Research Ltd (Collaboration)
- Atorika (Collaboration)
- Bruker Corporation (Collaboration)
- Newcastle University (Collaboration)
- Industrial Biotechnology Innovation Centre (Collaboration)
- Gencoa (Collaboration)
- University of East Anglia (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- UNIVERSITY OF EXETER (Collaboration)
- Syngenta International AG (Collaboration)
- Destiny Pharma (Collaboration)
- Ferring Pharmaceuticals (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- Severn Trent Water (Collaboration)
- British Fashion Council (Collaboration)
- University of Huddersfield (Collaboration)
- SETsquared Partnership (Collaboration)
- Systagenix Wound Management Manufacturing (Collaboration)
- Go South Coast Ltd (Collaboration)
- Government of Bangladesh (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- Oxford NanoImaging (Collaboration)
- Canterbury Christ Church University (Collaboration)
- Unilever (Netherlands) (Collaboration)
- Emerson & Renwick Limited (Collaboration)
- University of Hertfordshire (Collaboration)
- Fujifilm (Japan) (Collaboration)
- QUEEN MARY UNIVERSITY OF LONDON (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- AstraZeneca (Collaboration)
- UNIVERSITY OF ABERDEEN (Collaboration)
- PLYMOUTH MARINE LABORATORY (Collaboration)
- Health and Safety Executive (Collaboration)
- National metrology and testing laboratory (Collaboration)
- University of Ghent (Collaboration)
- UNIVERSITY OF LEEDS (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- University of Bristol (Collaboration)
- University of St Andrews (Collaboration)
- M Squared Lasers Ltd (Collaboration)
- UK HEALTH SECURITY AGENCY (Collaboration)
- FaraPack Polymers (Collaboration)
- Micreos (Collaboration)
- University of Sussex (Collaboration)
- University of Pune (Collaboration)
- Polysolar (Collaboration)
- University of the West of England (Collaboration)
- Teesside University (Collaboration)
- Steam-e Holdings Limited (Collaboration)
- Varicon Aqua Solutions Ltd (Collaboration)
- UNIVERSITY OF KENT (Collaboration)
- SASTRA University (Collaboration)
- Neem Biotech (Collaboration)
- Blueberry Therapeutics (Collaboration)
- Io-Cyte (Collaboration)
- Vitacress (United Kingdom) (Collaboration)
- ASTON UNIVERSITY (Collaboration)
- ESP Technology (Collaboration)
- Medipure Ltd (Collaboration)
- GLASGOW CALEDONIAN UNIVERSITY (Collaboration)
- DIAMOND LIGHT SOURCE (Collaboration)
- Ultrawave Ltd (Collaboration)
- University of Sheffield (Collaboration)
- DURHAM UNIVERSITY (Collaboration)
- Dwr Cymru Welsh Water (United Kingdom) (Collaboration)
- CRANFIELD UNIVERSITY (Collaboration)
- Kimal (Collaboration)
- Museum of Science and Industry (MOSI) (Collaboration)
- Bear Valley Ventures Ltd (Collaboration)
- Stavanger University Hospital (Collaboration)
- Neotherix Ltd (Collaboration)
- PUBLIC HEALTH ENGLAND (Collaboration)
- National Institute of Agricultural Technology (Collaboration)
- National Biofilms Innovation Centre (Collaboration)
- SHEFFIELD HALLAM UNIVERSITY (Collaboration)
- Wellcome Trust (Collaboration)
- QUEEN'S UNIVERSITY BELFAST (Collaboration)
- National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS) (Collaboration)
- Upperton Pharma Solutions (Collaboration)
- Defence Science & Technology Laboratory (DSTL) (Collaboration)
- IBioIC (Collaboration)
- Matoke Holdings (Collaboration)
- Pukka Herbs Ltd (Collaboration)
- EXTRONICS LTD (Collaboration)
- JNCASR Jawaharlal Nehru Centre for Advanced Scientific Research (Collaboration)
- Procter & Gamble (Collaboration)
- Columbia University (Collaboration)
- University of Portsmouth (Collaboration)
- ABERYSTWYTH UNIVERSITY (Collaboration)
- Perfectus Biomed Ltd. (Collaboration)
- National Physical Laboratory (Collaboration)
- Smiths Medical (Collaboration)
- LIVERPOOL HEART AND CHEST HOSPITAL (Collaboration)
- Scottish Universities Life Sciences Alliance (Collaboration)
- Chelsea Technologies Group (Collaboration)
- AQUALUTION SYSTEMS LTD (Collaboration)
- Cardiff University (Collaboration)
- Fixed phage limited (Collaboration)
- Historic England (Collaboration)
- NanoVibronix Inc (Collaboration)
- University of Helsinki (Collaboration)
- Technovent Ltd (Collaboration)
- Valeport (Collaboration)
- Pilkington Glass (Collaboration)
- CC Biotech (Collaboration)
- Georgia Institute of Technology (Collaboration)
- University of Manchester (Collaboration)
- UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST (Collaboration)
- King's College Hospital (Collaboration)
- YouSeq Ltd (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- University of Porto (Collaboration)
- NovaBiotics Ltd, UK (Collaboration)
- Altered Carbon Ltd. (Collaboration)
- 3M (United States) (Collaboration)
- Anacail Ltd (Collaboration)
- BioInteractions (Collaboration)
- De Montfort University (Collaboration)
- Princeton University (Collaboration)
- Engineering and Physical Sciences Research Council (EPSRC) (Collaboration)
- T-EDTA LTD (Collaboration)
- University of Edinburgh (Project Partner)
- University of Liverpool (Project Partner)
- University of Nottingham (Project Partner)
Publications
Alcalde-Rico M
(2018)
Role of the Multidrug Resistance Efflux Pump MexCD-OprJ in the Pseudomonas aeruginosa Quorum Sensing Response.
in Frontiers in microbiology
Alcalde-Rico M
(2020)
The impaired quorum sensing response of Pseudomonas aeruginosa MexAB-OprM efflux pump overexpressing mutants is not due to non-physiological efflux of 3-oxo-C12-HSL.
in Environmental microbiology
Alexander M
(2017)
Water contact angle is not a good predictor of biological responses to materials
in Biointerphases
Allen RJ
(2019)
Bacterial growth: a statistical physicist's guide.
in Reports on progress in physics. Physical Society (Great Britain)
| Title | #BiofilmAware social media assets |
| Description | Social media assets and headers to help raise awareness of what biofilms are and why they are so important and to promote the #BiofilmAware campaign. |
| Type Of Art | Artwork |
| Year Produced | 2020 |
| Impact | Social media assets and headers to help raise awareness of what biofilms are and why they are so important and to promote the #BiofilmAware campaign. |
| URL | https://www.biofilms.ac.uk/biofilmaware/ |
| Title | #BiofilmWeek social media assets |
| Description | Social media assets and headers to help raise awareness of what biofilms are and why they are so important and to promote #BiofilmWeek, an initiative which is part of the #BiofilmAware campaign. |
| Type Of Art | Artwork |
| Year Produced | 2021 |
| Impact | Social media assets and headers to help raise awareness of what biofilms are and why they are so important and to promote #BiofilmWeek, an initiative which is part of the #BiofilmAware campaign. |
| URL | https://www.biofilms.ac.uk/biofilmweek/ |
| Title | A New Weapon Against Pseudomonas aeruginosa, with Bhavik Bharochia from the University of Southampton. |
| Description | Video explaining biofilm research and societal impact. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.biofilms.ac.uk/pseudomonas-aeruginosa-a-new-weapon/ |
| Title | Additional file 1 of An improved bind-n-seq strategy to determine protein-DNA interactions validated using the bacterial transcriptional regulator YipR |
| Description | Additional file 1: Figure S1. SDS/PAGE gel image shows a single band of the His6-MBP tag of the expected size of 81 kDa purified by affinity and size exclusive chromatography. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2020 |
| URL | https://springernature.figshare.com/articles/MOESM1_of_An_improved_bind-n-seq_strategy_to_determine_... |
| Title | Additional file 1 of An improved bind-n-seq strategy to determine protein-DNA interactions validated using the bacterial transcriptional regulator YipR |
| Description | Additional file 1: Figure S1. SDS/PAGE gel image shows a single band of the His6-MBP tag of the expected size of 81 kDa purified by affinity and size exclusive chromatography. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2020 |
| URL | https://springernature.figshare.com/articles/MOESM1_of_An_improved_bind-n-seq_strategy_to_determine_... |
| Title | Antibiotic Resistance in Skin Wound Infections, with Snehal Kadam from the University of Hull. |
| Description | Video explaining biofilm research and societal impact. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.biofilms.ac.uk/antibiotic-resistance-infections/ |
| Title | Article and drawing produced by primary school children (J C Denis) |
| Description | 2 P7 children wrote and article and produced a drawing of the Edinburgh NBIC PI, following a series of events I organised. |
| Type Of Art | Artwork |
| Year Produced | 2020 |
| Impact | Very high quality science interview produced. |
| URL | https://blogs.ed.ac.uk/physics-astronomy/2020/09/21/interview-with-cait-macphee/ |
| Title | Battling Bacterial Vaginosis, with Ryan Kean from Glasgow Caledonian University. |
| Description | Video explaining biofilm research and societal impact. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.biofilms.ac.uk/bacterial-vaginosis/ |
| Title | Biofilm Brainhub website |
| Description | The Biofilm Brainhub was funded by the National Biofilms Innovation Centre (NBIC) Public Engagement Grant 2020-2021. |
| Type Of Art | Artistic/Creative Exhibition |
| Year Produced | 2021 |
| Impact | The website has been built with the support of the wider research community and features information on biofilms for a wide range of publics, through multiple clickable layers of information. We hope this will be the "go-to website" for anyone looking to learn about biofilms. |
| URL | https://biofilmbrainhub.co.uk/ |
| Title | Biofilm Embroidery series |
| Description | Series of 4 pieces of embroidery depicting biofilms as imagined by embroiderer: Ruby Tait Collaboration: Jean-Christophe Denis |
| Type Of Art | Artwork |
| Year Produced | 2022 |
| Impact | Embroiderer submitted embroidery as part of the NBIC Art Competition - and won. Alos, to be displayed at exhibition in 2023. |
| Title | Biofilm Image Gallery |
| Description | In January 2021 we launched our first biofilm photography competitions as part of our #BiofilmAware campaign, which works to raise awareness of NBIC and its research, and the many societal and economic impacts of biofilms. |
| Type Of Art | Artwork |
| Year Produced | 2021 |
| Impact | This biofilm image gallery contains a selection of images from our 'Biofilms in the lab' and 'Biofilms in Real Life' photography competitions. |
| URL | https://www.biofilms.ac.uk/biofilm-image-gallery/ |
| Title | Biofilm, Mutants and Mass Spectrometry, with Winifred Akwani from the University of Surrey. |
| Description | Video explaining biofilm research and societal impact. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.biofilms.ac.uk/mass-spectronomy-biofilm/ |
| Title | Bioiflms animation video. (J C Denis) |
| Description | Animation movie to describe the biofilms research in Edinburgh. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2020 |
| Impact | Animation movie to describe the biofilms research in Edinburgh. |
| URL | https://youtu.be/-MpueLFcC1I |
| Title | Biological Photovoltaics and Sustainability, with Maira Anam from the University of Nottingham. |
| Description | Video explaining biofilm research and societal impact. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.biofilms.ac.uk/biological-photovoltaics-and-sustainability/ |
| Title | Coccus Pocus 2019 |
| Description | Antibiotic resistance by pathogenic microorganisms is currently a major health concern, leading to a big rise of serious untreatable infections, especially in hospital environments. In addition, biofilms (slimy structures that microbes form around them) further protect the microbes against antibiotics, detergents and the attacks of our immune system. In October 2019, the Department of Biomedical and Forensic Sciences at the University of Hull launched an exciting scary story competition, Coccus Pocus 2019! The contestants were encouraged to write a short horror sci-fi story between 500 and 2,000 words, including antimicrobial resistance and microbial biofilms. |
| Type Of Art | Creative Writing |
| Year Produced | 2019 |
| Impact | Prizes were awarded for first, second and third places with the stories being published on the NBIC website. |
| URL | https://www.biofilms.ac.uk/coccus-pocus-2019-a-microbiology-inspired-scary-story-competition/ |
| Title | Coccus Pocus 2020 |
| Description | A horror sci-fi short story competition highlighting the importance of antibiotic resistance and biofilms. In an ambitious attempt to inform young people about the importance of antibiotic resistance and microbial biofilms, we will organise a horror sci-fi short story competition for this Halloween. The participants will be encouraged to write an engaging scary story, incorporating valid scientific information about AMR and biofilms. This will motivate them to read about these topics, understand the basic principles and use this information in their post-apocalyptic horror scenarios, in an educational and enjoyable way. |
| Type Of Art | Creative Writing |
| Year Produced | 2020 |
| Impact | Prizes were awarded for first, second and third places with the stories being published on the NBIC website. |
| URL | https://www.biofilms.ac.uk/coccus-pocus-2020-halloween/ |
| Title | Coccus Pocus 2021 |
| Description | A horror sci-fi short story competition highlighting the importance of antibiotic resistance and biofilms. In an ambitious attempt to inform young people about the importance of antibiotic resistance and microbial biofilms, we will organise a horror sci-fi short story competition for this Halloween. The participants will be encouraged to write an engaging scary story, incorporating valid scientific information about AMR and biofilms. This will motivate them to read about these topics, understand the basic principles and use this information in their post-apocalyptic horror scenarios, in an educational and enjoyable way. |
| Type Of Art | Creative Writing |
| Year Produced | 2021 |
| Impact | Prizes were awarded for first, second and third places with the stories being published on the NBIC website. |
| URL | https://www.biofilms.ac.uk/coccus-pocus-2021-winning-stories |
| Title | Combatting Cystic Fibrosis, with Declan Power from the University of Southampton. |
| Description | Video explaining biofilm research and societal impact. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.biofilms.ac.uk/cystic-fibrosis/ |
| Title | Complex Polymicrobial Biofilms, with Shaun Robertson, from the University of Nottingham. |
| Description | Video explaining biofilm research and societal impact. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.biofilms.ac.uk/complex-polymicrobial-biofilms/ |
| Title | Edinburgh Science Festival: Sherlock Holmes and the Biofilms Mystery |
| Description | Online activity pack: Sherlock Holmes needs your help to discover who broke into his apartment and why they did it! Can you use the clues to solve the mystery of the burglar? Use the clues and information provided about biofilms to find out WHO broke into Sherlock's apartment. |
| Type Of Art | Artistic/Creative Exhibition |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://storymaps.arcgis.com/stories/83be7dc3978d48f1932760c034f5afcf |
| Title | Forming Biofilms Within 3D Environments, with Eirini Velliou from University College London. |
| Description | Video explaining biofilm research and societal impact. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.biofilms.ac.uk/biofilms-within-3d-environments/ |
| Title | Girlguiding Dundee/WCAIR Virtual Sleepover: Science Camp! (Nicola Stanley-Wall) |
| Description | PEOPLE INVOLVED: A co-development between WCAIR researchers, the Girlguiding Dundee committee, and 2 senior female scientists from SLS WHAT WAS IT? A series of activity packs released over the course of a weekend to create the feeling of a sleepover. The packs were accompanied by a series of videos, a Teams Live event, and interaction on social media, particularly using a Facebook group |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | KEY OUTCOMES: 1600 people from across the UK signed up to take part, and the packs received over 6000 downloads. We had an incredibly busy weekend with thousands of images uploaded onto the Facebook group, and thousands of views on our YouTube videos. Well over 1000 people also signed up to receive their badge after the event. FUTURE PLANS: Continue our relationship with Girlguiding so that we can have an in-person sleepover in the future, and continue to use the resources developed for other projects, such as with Glasgow Science Centre. Quote: "Amazing range of activities and useful downloadable resources which we can use again. It was also a great way of introducing science to young people and to de-mystify it for them. So often it is taught in schools in such a dull way - excellent weekend! Virtual Sleepover attendee" |
| URL | https://discovery.dundee.ac.uk/en/publications/girlguiding-dundeewcair-virtual-sleepover-science-cam... |
| Title | Images of Microbiology |
| Description | A booklet containing a series of images taken by scientists based at the University of Dundee that highlight the microbes they work with. |
| Type Of Art | Artwork |
| Year Produced | 2021 |
| Impact | The images in the collection are part of a physical exhibition located at the Dundee Science Centre. |
| URL | https://discovery.dundee.ac.uk/ws/portalfiles/portal/58788913/23109_Microbe_Picture_Book_Accessible_... |
| Title | Interactive Biofilm Ontology Map |
| Description | We have devoted time across our industrial and academic communities to understand the language and terminology of biofilms, and this has been captured as an ontology on the MindManager platform. This was developed in consultation with 80 UK researchers (in industry and research institutions/universities) to document how they talk about and describe biofilm research, problems and opportunities. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2019 |
| Impact | Reference document to guide discussions on biofilm research, problems and opportunities. |
| URL | https://www.biofilms.ac.uk/biofilm-ontology/ |
| Title | International Biofilm Markets Infographics |
| Description | In the summer of 2020, we commissioned an independent study on international biofilm markets to further understand the economic significance of biofilms in the UK and globally. The study estimated expenditure associated with biofilms in 2019; information is not yet generally available for 2020 to quantify the impact of the COVID-19 pandemic. Biofilms are ubiquitous but particularly prominent in some sectors of the economy. These sectors form the focus of this study. We have used publicly available evidence to quantify economic activity relating to biofilms. The study assessed the focus industrial sectors of the National Biofilms Innovation Centre. The total economic impact was estimated to be almost $4,000bn globally and £45bn ($62Bn) in the UK. These are likely to be under-estimates of the impact of biofilms. For example, in healthcare whilst we identified $387bn of direct costs as a consequence of biofilms (5% of global healthcare expenditure). we know that prevention of infection (strongly linked to biofilm control) is a major goal of all healthcare procedures and so impacts significantly on the world's $7,800bn health related activity. We conservatively estimate the true total economic significance of biofilms is likely to be in excess of $5,000bn. We've created infographics to reflect the results of this study and show the huge impact biofilms have on our global economy. |
| Type Of Art | Artwork |
| Year Produced | 2021 |
| Impact | These highlight key facts and statistics relating to 6 international biofilm markets - personal care, human health, food processing, marine biofouling, oral care and homecare. |
| URL | https://www.biofilms.ac.uk/international-biofilm-markets/ |
| Title | MOESM1 of An improved bind-n-seq strategy to determine protein-DNA interactions validated using the bacterial transcriptional regulator YipR |
| Description | Additional file 1: Figure S1. SDS/PAGE gel image shows a single band of the His6-MBP tag of the expected size of 81 kDa purified by affinity and size exclusive chromatography. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2020 |
| URL | https://springernature.figshare.com/articles/MOESM1_of_An_improved_bind-n-seq_strategy_to_determine_... |
| Title | MicroBattle (µB): Microbiology themed card game |
| Description | MicroBattle Project was funded by the National Biofilms Innovation Centre (NBIC) Public Engagement Grant 2020-2021. MicroBattle (µB): Microbiology themed card game. |
| Type Of Art | Artistic/Creative Exhibition |
| Year Produced | 2021 |
| Impact | Resources for members of the public to gain understanding of biofilms. |
| URL | https://www.biofilms.ac.uk/microbattle-card-game/ |
| Title | Microbe Zone (Nicola Stanley-Wall) |
| Description | A physical exhibition, the microbe zone, located at Dundee Science Centre features images of microbes. Scientists at the University of Dundee alongside some collaborators at other Scottish Institutions contributed images of microbes that highlight their research. Short descriptions accompany the images to allow the reader to explore the wonderful world of microbiology. An associated 'Images of microbiology' booklet and activity book have been created. |
| Type Of Art | Artistic/Creative Exhibition |
| Year Produced | 2021 |
| Impact | New publications and new recognition of research using microbiology. |
| Title | Mighty Microbe |
| Description | A video of NBIC partner Katherine Fish, a Civil Engineer at the University of Sheffield talking about how she works with microbes, and describing how to make a Mighty Microbe toy. This video was made for the Maker{Future}'s 'Think Like An Engineer' initiative, funded by the Royal Academy of Engineering. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.youtube.com/watch?v=4B9_6PWA8io |
| Title | Molecular Microbe-Host Interactions, with Shi-qi An from the University of Southampton. |
| Description | Video explaining biofilm research and societal impact. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.biofilms.ac.uk/microbe-host-interactions/ |
| Title | Physics x Art |
| Description | Art exhibition featuring work created by student artists and inspired by physics research. The exhibition featured a gallery opening with over 70 attendees from various different backgrounds (Arts, Edinburgh public, Phyiscs). The exhibition was open from Friday, 14 October - Tuesday, 18 October which included a wider audience of passers-by, art students, College of Science and Engineering students, Edinburgh public. It also included outreach activities ('Build your own Biofilm). Featured art and sculptures related to biofilms (along with other projects). NBIC Collaborators: Jean-Christophe Denis; Cait MacPhee. |
| Type Of Art | Artistic/Creative Exhibition |
| Year Produced | 2022 |
| Impact | Closer cooperation with Edinburgh College of Arts. Art will be displayed in a new building of the University of Edinburgh, The Nucleus, during its official opening by Princess Anne and viewable pubilcally then. |
| Title | Raman Against Respiratory Infection, with Callum Highmore from the University of Southampton. |
| Description | Video explaining biofilm research and societal impact. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.biofilms.ac.uk/raman-respiratory-infection/ |
| Title | Safeguarding Water Quality for the Future, with Katherine Fish from the University of Sheffield. |
| Description | Video explaining biofilm research and societal impact. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.biofilms.ac.uk/water-quality/ |
| Title | Scales of Resistance video (Morgan Alexander) |
| Description | A short video presentation providing educational information regarding the issue of antibiotic resistance and the need to take effective action in the future. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2019 |
| Impact | Used as part of the Royal Society Summer Science Online programme promoting science to the general public. Morgan Alexander. |
| URL | https://cfvod.kaltura.com/p/1355621/sp/135562100/thumbnail/entry_id/1_y72nz7d1/version/100001/width/... |
| Title | Science Ceilidh |
| Description | Science Ceilidh-biofilms formation, shows how microbiomes formed into biofioms. |
| Type Of Art | Performance (Music, Dance, Drama, etc) |
| Year Produced | 2018 |
| Impact | It allows participants and viewers to have a more direct understanding of biofilms formation and how they are different from normal individual microbiomes, and how physics might be able to tackle the issue. |
| URL | http://www.scienceceilidh.com/physics |
| Title | Science For All Takes Many Hands (Nicola Stanley-Wall) |
| Description | A common factor of many public engagement encounters is that they would not be possible without contributions from many people with diverse roles and skills. If we take the signature outreach event of the Division of Molecular Microbiology Magnificent Microbes as an example, there are 25 different groups of people involved to allow this long-standing public engagement event to achieve its goals. Illustrator Daisy MacGowan created Science For All Takes Many Hands which highlights and celebrates the breadth of the contributions from across the University of Dundee and beyond. These roles come from estate and buildings, health and safety, finance, contracts, research finance, research innovation services, cleaning services, and many more. Look at the illustration to explore the roles in more depth. It is important that we all recognise that public engagement by researchers is the result of teamwork and the collective effort is what allows success. |
| Type Of Art | Artwork |
| Year Produced | 2020 |
| Impact | Stimulate change in scientist and public perception. The recognition that many people in divergent roles have valuable contributions to science outreach. Nicola Stanley-Wall |
| URL | https://discovery.dundee.ac.uk/en/publications/science-for-all-takes-many-hands |
| Title | Sculptures (4) |
| Description | 3d Print and Resin Sculpture series (earth, europa, space, mars) of imagined biofilms - artist: Catriona Clark Collaboration: Jean-Christophe Denis; Cait MacPhee |
| Type Of Art | Artwork |
| Year Produced | 2022 |
| Impact | Sculptures were included in an exhibition in October 2022 and will be included in an exhibition at the University of Edinburgh in 2023, at the opening of a new building, which will be officially opened by Princess Anne. |
| Title | Super biomaterials to fight superbugs (Morgan Alexander) |
| Description | A short animated video showing how Nottingham University are trying to find novel surface coatings that prevent superbugs sticking and building slime city communities called biofilms. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2019 |
| Impact | Used as part of the Royal Society Summer Science Online programme promoting science to the general public. Morgan Alexander. |
| URL | https://cfvod.kaltura.com/p/1355621/sp/135562100/thumbnail/entry_id/1_00ytd3sg/version/100001/width/... |
| Title | The Little Book of Fermentation |
| Description | Following an NBIC-funded public engagement and outreach project (NBIC PE&O Award: PE014 Hands on Biofilm!), this book was created for an NBIC event at the Museum of Science and Industry. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2022 |
| Impact | Not known. |
| Title | University of Edinburgh Biofilm Innovation website |
| Description | A website from the University of Edinburgh which showcases the important biofilm research taking place across the institution. The site also includes a number of educational and outreach resources available for download. |
| Type Of Art | Artistic/Creative Exhibition |
| Year Produced | 2021 |
| Impact | A website from the University of Edinburgh which showcases the important biofilm research taking place across the institution. |
| URL | https://www.ed.ac.uk/edinburgh-biofilms-innovation |
| Title | Unruly Objects |
| Description | Exhibition at Victoria and Albert Museum 24-25 September 2022 presenting the work completed during an NBIC funded public engagement and outreach project. Discover how BioArt can help mitigate climate change and join the drop-in lab to create your own tiny marble sculpture painted with 'living latex'. |
| Type Of Art | Artistic/Creative Exhibition |
| Year Produced | 2022 |
| Impact | Unruly Objects explores ways of capturing carbon using cyanobacteria encapsulated into a kind of 'living latex' to mitigate climate change. It also investigates the possibility of conserving antiquities through the enhancement of their microbiomes, the place of BioArt within museums, and the use of blockchain technologies to store conservation data. Project developed by Anna Dumitriu in collaboration with Simone Krings, Dr. Suzie Hingley-Wilson and Professor Joseph Keddie from the University of Surrey. Join the Unruly Objects Lab to create your own tiny marble 'unruly objects' painted with 'living latex' and keep your tiny sculpture or leave it with us to become part of a new BioArt work. Activity open to adults and children (5+ years) accompanied with an adult. |
| URL | https://www.vam.ac.uk/event/4KODrMy2bB/unruly-objects |
| Title | Using AI to Detect Bacteria in Wastewater, with Gavin Melaugh, from the University of Edinburgh. |
| Description | Video explaining biofilm research and societal impact. |
| Type Of Art | Artefact (including digital) |
| Year Produced | 2021 |
| Impact | Public engagement. |
| URL | https://www.biofilms.ac.uk/using-ai-to-detect-bacteria/ |
| Title | Why Should I brush my teeth? |
| Description | Activity with the aim to Introduce biofilms in the context of teeth hygiene. Works well for attracting people at a stall, as very noticeable setup and intriguing. |
| Type Of Art | Artistic/Creative Exhibition |
| Year Produced | 2020 |
| Impact | Used for public engagement. |
| Description | NBIC has created a pioneering and truly national centre with international reach. We have adopted an inclusive approach that has brought together the original four lead Universities (Edinburgh, Liverpool, Nottingham and Southampton), and a partnership that has expanded to include 59 associate research institutions (RIs), and support from a growing base of >150 small, medium and large companies. This has brought the UK an unprecedented set of capabilities, connectedness and exploratory power that has allowed us to be a crucible and catalyst for innovation and to achieve impact on a global stage. NBIC has created a global brand, linked to the world's leading biofilm RIs. We have signed Memoranda of Understanding (MOU) with four of these centres and are well connected with others. NBIC is proud to be recognised internationally for its innovation and leadership role in biofilms through international webinars and landmark work on defining the global research and commercial opportunity. Our impact is evidenced by our company interactions and partnering, our portfolio of 80 Proof of Concept (POC) projects, 34 Flexible Talent Mobility Awards (FTMA), and collaborative partnership awards with the USA, Singapore and Argentina. NBIC is also educating the next generation of researchers and entrepreneurs and driving the UK engine to influence the policy and research agenda for biofilms. Only via the creation of NBIC has this national connectivity and global impact been realised, hence advancing the BBSRC Biofilm strategy. |
| Exploitation Route | NBIC will build on its collective strengths as the UK's national centre to drive and expand its global leadership at the international forefront of research, training and innovation in biofilm technologies, addressing the grand challenges important to the UK's future prosperity. We will work with our partnership of 63 research institutions and >150 companies, established under Phase 1, and transition to an approach that develops deeper and more strategic collaborations, focused and co-opted teams, and jointindustry programs to address strategic priorities and deliver on shared sectoral roadmaps. Key overall objectives that will be addressed during Phase 2 will be to: - Tackle the biggest open research and innovation questions in the field and deliver global leadership, cross-cutting enabling platforms and breakthrough science and innovation to Prevent, Detect, Manage and Engineer (PDME) biofilms. - Drive the adoption of flexible, interdisciplinary solutions across industry sectors, addressing societal and economic grand challenges, including climate change, NetZero, food and water safety and security, and healthcare. We will establish the Joint Industry Programs addressing pre-competitive research to progress agreed roadmaps. - Enter into active partnerships with government and policy makers to deliver step-changes in standards and regulations for novel biofilm solutions. We will deliver model biofilms, analytical methods and recommendations within 3 years and support industry-government discussions on regulation through providing a strong evidence base to underpin policy. We will develop new international standards and test protocols driving growth and trade in biofilm products and technologies by Year 5. - Deliver a roadmap for new biofilm biobanking resources and infrastructure, which have been identified by our community as critical to underpin basic science programmes as well as accelerate product development and commercialization. - Provide global leadership via enhanced interactions with established centres in Singapore, US and the EU, while nucleating new relationships and networks with countries with rapidly expanding economic and healthcare challenges. - Train the next generation of thought leaders and entrepreneurs by delivering a co-created programme of training that addresses key skills gaps identified by our industrial and academic communities. - Accelerate the translation of knowledge-rich solutions to industry and the market via academic-industry collaborations, and then driving innovation and growth via close engagement with regional partners, thus contributing to the 'levelling-up' agenda. Companies that we work with will use the outputs of our work to launch new products, processes and services. Together with our partners we will maximise the commercial impact of world-class knowledge developed by our research and industry base to deliver economic and societal impact for the UK. |
| Sectors | Aerospace Defence and Marine Agriculture Food and Drink Digital/Communication/Information Technologies (including Software) Education Energy Environment Healthcare Government Democracy and Justice Manufacturing including Industrial Biotechology Culture Heritage Museums and Collections Pharmaceuticals and Medical Biotechnology Transport |
| URL | http://www.biofilms.ac.uk |
| Description | The vision for the National Biofilms Innovation Centre is to create a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. By harnessing our interdisciplinary expertise and infrastructure across the UK, we will create the next generation of researchers and entrepreneurs to deliver growth and wealth creation. We are creating a pioneering and truly national centre, with an inclusive strategy that has brought together the original four lead Universities, a partnership that has expanded to include 63 associate research organisations, and support from a growing base of >200 small, medium and large companies. This brings an unprecedented set of capabilities, connectedness and exploratory power that carries a huge potential for innovation that will allow us to lead on a global stage. NBIC is creating a global brand, intimately linked with the world's leading biofilm research institutions. We have signed a Memoranda of Understanding (MOU) with three of these centres. NBIC aims to be recognised internationally for its innovation and collaborative research in biofilms. Our early impact is evidenced by our company interactions, partnering, our portfolio of 81 Proof of Concept (POC) projects, and workshops. We are also educating the next generation of researchers and entrepreneurs and starting to drive the policy and research agenda for biofilms in the UK. Our vision for advancing biofilm research and skills training builds on the strategic themes of Prevention, Detection, Managing and Engineering of biofilms. Together with our academic and industry partners, we are working to define the key global challenges and scientific priorities within these themes, and we will continue to refine and develop our objectives according to industry needs. We have built a UK-wide cohort of Interdisciplinary Research Fellows (IRFs) to deliver on these scientific priorities. Key challenges defined within these themes include: In Prevention we aim to design a new generation of surfaces and materials to prevent microbial adhesion and/or biofilm formation; in Detection to deliver a step change in the ability to detect biofilms directly, in-situ and at the point-of-use in field-based contexts and in close-to-patient care; in Manage to accelerate the development of successful treatments, which target the biofilm life cycle-dynamics; and in Engineer to harness the benefits of complex microbial consortia from knowledge of their composition, function, ecology and evolution. Our vision is for NBIC to be the natural route for organisations to target their open innovation activity related to biofilm management or exploitation across the UK. We are connecting experts, simplifying knowledge transfer and catalysing collaboration to address key issues on biofilm prevention, detection, management and engineering. Working with industry, NBIC is already starting to produce sector roadmaps, identify the unmet needs of the sectors, and the key scientific, commercial, technical and regulatory barriers to meet them. The roadmaps will provide clear direction to evolve the NBIC science strategy over time. Our vision is that the research institutions in NBIC will create and share the national infrastructure that UK industry needs and that NBIC will collaborate with companies across a wide range of sectors under a permissive IP framework that anchors IP within the team that creates it, and rewards increasing commitment from companies. We have built this approach to IP into our contracts for our POC calls. Through site visits and discussions, we are building an understanding of the capabilities of all our partner research institutions to be able to capture current infrastructure and begin to identify gaps. A key part of our vision is to transform the research and entrepreneurial capability across the UK in the biofilm community through our IRFs, Doctoral Network and entrepreneurial training, addressing the skills gap in multidisciplinarity, entrepreneurship, responsible innovation, regulatory knowledge and leadership identified across the multi-sectorial biofilm field. The NBIC vision is one we have shared widely through our face-to-face contact with researchers, engagement with companies, our communications, consultations, workshops and social media. Our wider vision has been refined in response to the views of the wider community and through input from our Advisory Groups. A clear measure of the community support we have for this vision is the active and firm support from the UK Research and industrial base via their direct engagement in our work. |
| First Year Of Impact | 2017 |
| Sector | Aerospace, Defence and Marine,Agriculture, Food and Drink,Chemicals,Communities and Social Services/Policy,Construction,Education,Energy,Environment,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology,Transport |
| Impact Types | Societal Economic Policy & public services |
| Description | Active participation in the International Biofilm Standards Task Group (Paulina Rakowska) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| URL | https://www.biofilms.ac.uk/international-standards-task-group/ |
| Description | Approaches to Biofilm-associated Infections: Evaluating Gaps in Standardized Methods for Clinical Applications. Credits for continuing education webinar. (Paul Stoodley) |
| Geographic Reach | North America |
| Policy Influence Type | Influenced training of practitioners or researchers |
| URL | https://education.healthtrustpg.com/calendar/2454/2020-06-21/ |
| Description | Attendance at policy / strategy meeting with BBSRC to influence and contribute to the Microbiome Research Strategy (Mark Richardson) (Jan - Mar 2020) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Attendance at policy / strategy meeting with BBSRC to influence and contribute to the Microbiome Research Strategy. |
| Description | BBSRC Microbiome Research Strategy (Jeremy Webb) (Jan - Mar 2020) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Attendance at policy / strategy meeting with BBSRC to influence and contribute to the Microbiome Research Strategy. |
| Description | Board Member, Audit and Risk committee and EPSRC Value for Money committee, Rosalind Franklin Institute (Peter Smith) |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Membership of a guideline committee |
| Impact | Formation of a new national research institute working at the interface of life sciences and engineering. |
| Description | Citation in a clinically-focused review (Dario Carugo) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical reviews |
| URL | https://turkishjournalofurology.com/en/problems-and-solutions-of-stent-biofilm-and-encrustations-a-r... |
| Description | Co-supervise a PhD candidate (Peng Bao) |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Kyle has trained for the use of multiple instruments. He has gone to Bruker (Berlin) for an on-site training on BioAFM. Kyle has progressed well with his PhD study and he has built a solid research plan. |
| Description | Cosmetics Cluster UK Ltd (Katerina Steventon) |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Via organising the joint webinar(s), NBIC enabled CCUK members to access new academic and industry expertise, and gain better understanding of market trends, claim substantiation and regulatory insights in the area of microbiome in personal care. The collaboration also informed CCUK about NBIC remit, initiatives and approach to innovation, to share this knowledge widely. |
| URL | https://www.youtube.com/watch?v=js3SF_j2zlo |
| Description | Cystic Fibrosis Syndicate in AMR (Mark Richardson) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Contribution to a national consultation/review |
| Impact | To address these challenges, the CF Syndicate in AMR will catalyse new research efforts and build capacity in the following areas: Streamline and enable access to clinically relevant samples for the preclinical screening and testing of CF antimicrobials Map and validate the preclinical screening and testing pathways to provide faster routes to bring CF antimicrobials to the clinic Develop guidance for industry on the key characteristics and requirements that CF antimicrobials should meet in order to address the needs and priorities of people with CF, through the development of Target Product Profiles. |
| URL | https://md.catapult.org.uk/syndicates/cystic-fibrosis-syndicate-in-antimicrobial-resistance/ |
| Description | Cystic Fibrosis Syndicate on AMR with the Cystic Fibrosis Trust and Medicines Discovery Catapult Syndicate Steering committee (Miguel Camara) |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Impact | We have designed a strategy to accelerate the discovery, commercialisation and implementation of novel therapeutic approaches for patients with cystic fibrosis. I am representing NBIC within this committee. We are working on the generation of strain biobanks for patients, Target Products Profiles for CF and drug discovery platforms which can be accessible to the general scientific and industrial community. |
| Description | EPSRC Beyond Antibiotics International advisory board (Paul Stoodley) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Formation of the International Biofilm Standards Task Group with our partners at CBE and SNBC (Jeremy Webb and Mark Richardson) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| URL | https://www.biofilms.ac.uk/international-standards-task-group/ |
| Description | IBRG (INTERNATIONAL BIODETERIORATION RESEARCH GROUP) Advisory Committee (Mark Richardson) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Membership of this group has allowed me alongside our IBSTG membership to demonstrate that NBIC is well engaged with the wider biofilm sector and allowed me to gain membership and chairmanship of a BSI technical advisory group. |
| URL | https://www.ibrg.org/Default.aspx |
| Description | Invited to UK-Singapore strategic talks representing global NBIC-SCELSE partnership. Government-to-Government discussions involving FCO, BEIS, Innovate UK, NRF (Jeremy Webb) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Involvement in the KTN Special interest group on the Microbiome across multiple sectors to aid in support of business progress and academic translation. (Mark Richardson) |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | Joint Research Strategy Board, University of Southampton and University Hospital Southampton (Peter Smith) |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Membership of a guideline committee |
| Impact | Coordinating clinical, health and research activities across the University of Southampton and the University of Southampton foundation Trust. |
| Description | KTN-NBIC Workshop on Biofilms and formal Report (Rasmita Raval) |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| URL | https://admin.ktn-uk.co.uk/app/uploads/2018/05/Biofilm-Workshop-Report-May2018.pdf |
| Description | Local Enterprise Partnership Innovation South Strategic Regional Industrial Policy. (Peter Smith) |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | MedTech Market Access (Peter Smith) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Better informed start up and SME community on the processes and pitfalls of developing a Medtech product through to deployment. |
| Description | Member of the Cystic Fibrosis Trust Strategic Implementation Board (Miguel Camara) |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Being a member of this Board I have been involved in the selection of the awards for Strategic Research Centres which are key to develop new treatments for cystic fibrosis, influencing clinical guidelines and provide training for early career researchers. |
| Description | Member of the International Advisory Council for Cluster for Pioneering Research (CPR) at RIKEN, Japan (Rasmita Raval) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://www.riken.jp/en/news_pubs/pubs/reports/cpr/index.html |
| Description | Methodology - The methodology used in this project can provide a quick and accurate screening method for the generation of ROS within the TAED/H2O2 system. (Claudio Lourenco) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| URL | https://discovery.ucl.ac.uk/id/eprint/10112700/ |
| Description | Microbiome Innovation Network Steering Group (Mark Richardson) |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| URL | https://ktn-uk.org/agrifood/microbiome/ |
| Description | Participation in BSI CH/216/1 Standards meeting . Influencing Standards (Mark Richardson) |
| Geographic Reach | Europe |
| Policy Influence Type | Membership of a guideline committee |
| Impact | NBIC on behalf of IBSTG is now on the BSI committee for reviewing antiseptic / disinfectant testing standards . This feeds in CEN, We aim to try and influence the adoption of Biofilm relevant testing in these standards. |
| URL | https://standardsdevelopment.bsigroup.com/committees/50081157 |
| Description | Participation in IBBS expert panel on standards and regulations (Mark Richardson) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Impact | This was an international webinar expert panel discussing the need for innovation in standards and regulations in a range of fields and how this could be coordinated internationally. Follow up discussions are happening. |
| Description | Participation with NIBSC and MHRA on standard setting (Mark Richardson) |
| Geographic Reach | Europe |
| Policy Influence Type | Membership of a guideline committee |
| Description | Pitch to Health Secretary Matt Hancock for microbubble decontamination prototype for intensive sterilization of microbes and viruses |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | SCELSE Scientific Advisory Board |
| Geographic Reach | Asia |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | SoCO BIO DTP (Mark Richardson) |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Chairing Non Exec board of BBSRC funded DTP and able to influence the training of doctoral students. |
| URL | https://southcoastbiosciencesdtp.ac.uk/ |
| Description | Society for Applied Microbiology Regulatory Standards (Jeremy Webb) (Dec 2019 - Mar 2020) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Meetings and discussions of the regulatory needs in the food environment with view to a workshop and coordinated policy of influence on regulatory standards . |
| Description | Supervision of a third-year student on the course of Chem366 (Peng Bao) |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Through this course, Hamza has gained basic experimental skills, knowledge of safety rules in the lab, a better understanding of the research environment, and experience in scientific report writing and public presentation. |
| Description | The Biofilm - Associated Impact of Surgical Outcomes. Continuing credit course for medical practioners. (Paul Stoodley) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| URL | https://education.healthtrustpg.com/calendar/on-demand-the-biofilm-associated-impact-on-surgical-out... |
| Description | The Environmental Biotechnology Network (EBNet) Steering Group (Will Green) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://ebnet.ac.uk/ |
| Description | UK MoD surface fleet hull management policy |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | UK-Singapore Bio-Institute review panel. BEIS, Innovate UK proposal for A Bio-incubator partnership with UK. (Jeremy Webb) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | UTI Patient Experience Survey |
| Geographic Reach | National |
| Policy Influence Type | Contribution to new or improved professional practice |
| Description | University of Southampton and University Hospital Southampton Foundation Trust COVID-19 Assessment Panel (Peter Smith) |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Membership of a guideline committee |
| Impact | Research and clinical assessment panel to fund and focus activities on the Covid-19 pandemic and possible interventions, or discouraging activity that would defocus the response. |
| Description | Wessex Health Partners Working Group, Lead discovery (Peter Smith) |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Membership of a guideline committee |
| Impact | Coordination of Wessex biomedical discovery, translation and innovation across all Universities and NHS Hospital Trusts. |
| Description | Wessex Regional Life Sciences Opportunities for Enterprise (Peter Smith) |
| Geographic Reach | National |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Description | iiCON Infection Innovation Consortium (Rasmita Raval) |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Contribution to new or Improved professional practice |
| URL | https://www.infectioninnovation.com/about/ |
| Description | 22ROMITIGATIONFUNDLiverpool |
| Amount | £283,000 (GBP) |
| Funding ID | BB/X51200X/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2022 |
| End | 04/2023 |
| Description | A Sludge Characterisation Platform (BBSRC IAA) |
| Amount | £44,742 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 08/2021 |
| Description | A high-content screen for novel small molecules that inhibit antibiotic-resistant bacterial infection (Shi-Qi An) |
| Amount | £20,000 (GBP) |
| Organisation | Wessex Medical Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 09/2021 |
| Description | A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens |
| Amount | £10,000 (GBP) |
| Funding ID | BB/W018497/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2022 |
| End | 06/2023 |
| Description | Advanced live imaging for the Eastern ARC with dual inverted light-sheets and AI-led analysis |
| Amount | £481,950 (GBP) |
| Funding ID | BB/W020033/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2022 |
| End | 07/2023 |
| Description | Antibiofilm Wound Dressings Designed to Prevent Infection and Minimize the Risk of Bacteraemia and Sepsis (Ronan McCarthy) |
| Amount | £100,000 (GBP) |
| Funding ID | SBF006\1040 |
| Organisation | Academy of Medical Sciences (AMS) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2021 |
| End | 08/2024 |
| Description | Assessment of Nanocin in UTI co-Biofilms (Isabelle Papandronicou) |
| Amount | £12,000 (GBP) |
| Organisation | University College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2023 |
| End | 04/2023 |
| Description | BBSRC Impact Acceleration Award via University of Warwick (PI) Mesoporous materials for antibiotic delivery into bacterial biofilm with industrial partner Brentapharm (Freya Harrison) |
| Amount | £3,996 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2022 |
| End | 03/2022 |
| Description | BBSRC Impact acceleration award (University of Edinburgh, Gavin Melaugh, BBSRC IAA PIII089) |
| Amount | £29,712 (GBP) |
| Funding ID | BBSRC IAA PIII089 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2021 |
| End | 02/2022 |
| Description | Benchmarking different antibacterial technologies using an oral in vitro system (Jeremy Webb) |
| Amount | £160,000 (GBP) |
| Organisation | Unilever |
| Sector | Private |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 11/2019 |
| Description | Biofilm Resistant Liquid-like Solid Surfaces in Flow Situations |
| Amount | £457,503 (GBP) |
| Funding ID | EP/V049615/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2022 |
| End | 02/2025 |
| Description | Biofuel generation from CO2 by using microbial electrolysis system (Loughborough University, Eileen Yu) |
| Amount | ¥100,000 (CNY) |
| Organisation | Dalian National Laboratory for Clean Energy |
| Sector | Public |
| Country | China |
| Start | 01/2020 |
| End | 12/2021 |
| Description | COLLABORATIVE TRAINING PARTNERSHIPS (CTP2) |
| Amount | £7,025,368 (GBP) |
| Funding ID | BB/W009374/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2022 |
| Description | Combined ultrasonically activated water stream and novel disinfectant for vCJD decontamination of re-usable medical instruments (Bill Keevil) |
| Amount | £820,000 (GBP) |
| Funding ID | PR-R17-0916-23005 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2021 |
| Description | DNA based super-resolution microscopy for bacterial cell surface nanoscale mapping |
| Amount | £11,920 (GBP) |
| Funding ID | IES\R2\222107 |
| Organisation | The Royal Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2022 |
| End | 10/2024 |
| Description | Developing stochastic models of micro-plastic associated biofilm growth (Miguel Camara) |
| Amount | £6,306 (GBP) |
| Organisation | University of Cassino and Southern Lazio |
| Sector | Academic/University |
| Country | Italy |
| Start | 03/2019 |
| End | 08/2019 |
| Description | Development and validation of biofilm model to establish the effect of chemical and physical treatments on cellular viability (Miguel Camara) |
| Amount | £12,457 (GBP) |
| Organisation | Melbec Microbiology Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 02/2021 |
| End | 01/2023 |
| Description | Development of a Moving Membrane Bioreactor (MMBR) for the Automated Cultivation and Harvest of Algae Grown as a Biofilm (Felix Ciceron) |
| Amount | £135,333 (GBP) |
| Organisation | Plymouth Marine Laboratory |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 08/2022 |
| Description | Development of antimicrobial peptides against Gram-negative antibiotic resistant pathogens |
| Amount | £17,221 (GBP) |
| Funding ID | MC_PC_MR/T029552/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 03/2023 |
| Description | Development of outreach material for Nottingham NBIC outreach and public engagement (Miguel Camara) |
| Amount | £2,000 (GBP) |
| Organisation | University of Nottingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 12/2018 |
| End | 04/2019 |
| Description | Development of outreach material for Nottingham NBIC outreach and public engagement - Nottingham University Institute of Policy and Engagement |
| Amount | £2,000 (GBP) |
| Organisation | University of Nottingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 12/2018 |
| End | 04/2019 |
| Description | Development of rapid testing technology to increase food security (Bill Keevil & MolEndoTech) |
| Amount | £192,206 (GBP) |
| Funding ID | 77477 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 06/2021 |
| Description | Development of rapid testing technology to increase food security (Callum Highmore) |
| Amount | £249,905 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 06/2021 |
| Description | Development of synthetic biofilm for calibrating the effect of coatings on reducing marine viscoelastic drag. (University of Southampton, Paul Stoodley) |
| Amount | £87,500 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 08/2022 |
| Description | Diagnostic biomarkers of gut microbiome-associated phenotypes predictive of healthy aging and neurodegenerative disease |
| Amount | £1,500,000 (GBP) |
| Funding ID | 303109 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 12/2023 |
| Description | Direct Industrial Funding (Robin Thorn) |
| Amount | £200,000 (GBP) |
| Organisation | Creo Medical Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 02/2021 |
| End | 02/2022 |
| Description | Do Host Microbe Interactions Accelerate Age-Related Cognitive Decline (PhD studentship) |
| Amount | £100,000 (GBP) |
| Funding ID | BB/T008768/1, studentship 2441683 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2021 |
| End | 09/2024 |
| Description | Does irrigating chronic wounds with a liquid acoustic stream (LAS) improve healing? |
| Amount | £20,800 (GBP) |
| Organisation | Southampton NIHR Biomedical Research Centre in Nutrition |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 06/2021 |
| Description | Drug interactions in the gut microbiome (PhD studentship) |
| Amount | £87,000 (GBP) |
| Organisation | University of Southampton |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 09/2026 |
| Description | EMBO BACNET21 Conference (Nicola Stanley-Wall) |
| Amount | € 35,000 (EUR) |
| Organisation | European Molecular Biology Organisation |
| Sector | Charity/Non Profit |
| Country | Germany |
| Start | 09/2021 |
| End | 09/2022 |
| Description | EMBO Bacterial Networks conference grant |
| Amount | £32,795 (GBP) |
| Funding ID | w21/22 |
| Organisation | European Molecular Biology Organisation |
| Sector | Charity/Non Profit |
| Country | Germany |
| Start | 06/2022 |
| End | 12/2022 |
| Description | EMBO LONG TERM FELLOWSHIP (University of Dundee, Nicola Stanley-Wall, ALTF 471-2020) |
| Amount | £185,189 (GBP) |
| Funding ID | ALTF 471-2020 |
| Organisation | European Molecular Biology Organisation |
| Sector | Charity/Non Profit |
| Country | Germany |
| Start | 06/2020 |
| End | 06/2022 |
| Description | EPSRC DTP Early Career Researcher Competition, Understanding Microbiological Risks of Urban Flooding (University of Edinburgh, Isabel Doutelero) |
| Amount | £80,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 05/2024 |
| Description | EPSRC IAA - Anti-Viral Surfaces and Materials |
| Amount | £20,000 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 10/2020 |
| Description | EPSRC Impact Acceleration Account (IAA) (Susana Direito 2022) |
| Amount | £1,980,071 (GBP) |
| Funding ID | EPSRC IAA PIV078 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 06/2022 |
| Description | EPSRC Impact Acceleration Account (IAA) Antimicrobial Contact Lens Cases (Raechelle D'Sa) |
| Amount | £15,000 (GBP) |
| Funding ID | EP/R511729/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 07/2019 |
| Description | EPSRC Impact Acceleration Account (IAA) Plasma activated aerosols for on-demand rapid sanitisation (Heather Allison) |
| Amount | £14,678 (GBP) |
| Funding ID | EPSRC IAA 2020 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 10/2020 |
| Description | EPSRC Impact Acceleration Account (University of Edinburgh, Susana Direito, EPSRC IAA PIII008) |
| Amount | £16,615 (GBP) |
| Funding ID | EPSRC IAA PIII008 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 09/2018 |
| Description | EPSRC Impact Acceleration Account - Anti-Viral Surfaces and Materials |
| Amount | £20,000 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 10/2020 |
| Description | EPSRC Impact Acceleration Account, Travel and Events Funding (University of Edinburgh, Susana Direito, EPSRC lAA Pll!063 Direito) |
| Amount | £2,304 (GBP) |
| Funding ID | EPSRC lAA Pll!063 Direito |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 11/2019 |
| Description | Engineering Novel Imaging Technologies for Reproductive Health: Transforming IVF outcomes |
| Amount | £244,593 (GBP) |
| Funding ID | EP/R041814/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2020 |
| Description | Establishment of Cryo-EM Screening Facility At University Of Dundee (Nicola Stanley-Wall) |
| Amount | £1,000,000 (GBP) |
| Funding ID | 223816/Z/21/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2021 |
| End | 12/2026 |
| Description | Evaluation of a stabilised hypochlorous for decontamination of root canal surfaces (Heather Allison) |
| Amount | £45,000 (GBP) |
| Organisation | Dentosafe-T LTD |
| Sector | Private |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 01/2019 |
| Description | FELS Knowledge Exchange and Enterprise Funding Skin Health and Mental Health/Wellbeing: A Cross-Functional Workshop and Structured Industry Interviews (Katerina Steventon) |
| Amount | £12,600 (GBP) |
| Organisation | University of Southampton |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 07/2022 |
| Description | Formulated Materials for Infectious Disease Prevention |
| Amount | £3,300,000 (GBP) |
| Organisation | European Commission |
| Department | European Regional Development Fund (ERDF) |
| Sector | Public |
| Country | Belgium |
| Start | 07/2020 |
| End | 07/2023 |
| Description | Formulated Materials for Infectious Disease Prevention (Rasmita Raval) |
| Amount | £3,300,000 (GBP) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 07/2020 |
| End | 07/2023 |
| Description | Global Challenges Research Fund (GCRF) - Antimicrobial point of use water filtration in India (Raechelle D'Sa) |
| Amount | £76,676 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 06/2021 |
| Description | Global Challenges Research Fund (GCRF) - Point of use water filtration (Raechelle D'Sa) |
| Amount | £20,000 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 03/2019 |
| Description | Gut bacteria and the brain: the surprising impact of bacteriophages (PhD studentship) |
| Amount | £100,000 (GBP) |
| Funding ID | BB/T008768/1, studentship 2596661 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2022 |
| End | 09/2025 |
| Description | ICURe Innovation to Commercialisation of University Research Cohort 40 biofilms sprint - Exploit Phase 2 |
| Amount | £11,958 (GBP) |
| Organisation | University of Nottingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2022 |
| End | 03/2023 |
| Description | Impact Acceleration Award |
| Amount | £19,928 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2023 |
| End | 07/2023 |
| Description | Impact Accelerator Account- PoC grant |
| Amount | £74,484 (GBP) |
| Organisation | University of Nottingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 12/2023 |
| Description | Infections in complex physical environments: Life and death in the sinuses (Bartlomiej Waclaw) |
| Amount | £2,172,244 (GBP) |
| Funding ID | EP/W023881/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 03/2025 |
| Description | Innovate UK (TS/P004512/1) (Rasmita Raval) |
| Amount | £521,000 (GBP) |
| Funding ID | TS/P004512/1 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2019 |
| Description | Innovate UK TS/P013716/1 (Rasmita Raval) |
| Amount | £350,000 (GBP) |
| Funding ID | TS/P013716/1 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 09/2019 |
| Description | Innovate UK Temp Framework Aug 2020 - Anti-viral transparent adhesive protection for Touch Screens to help in the fight against COVID-19 |
| Amount | £224,011 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2020 |
| End | 08/2021 |
| Description | Label-free Super-resolution in Light Sheet Microscopy (Impact Acceleration Account) |
| Amount | £60,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Lactam AMR Elucidating the Molecular Mechanisms of Action and Resistance of microbes to Unilever Anti-biofilm Lactam Technology |
| Amount | £100,279 (GBP) |
| Funding ID | BB/T509127/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 09/2023 |
| Description | Lighting the Way to a Healthy Nation - Optical 'X-rays' for Walk Through Diagnosis & Therapy |
| Amount | £5,577,754 (GBP) |
| Funding ID | EP/T020997/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2020 |
| End | 05/2023 |
| Description | MICRA Innovation Funding (Veeren Chauhan) |
| Amount | £25,000 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 06/2021 |
| Description | Modulating Skin Bacteria to Improve Wound Healing in the Elderly (Holly Wilkinson) |
| Amount | £85,000 (GBP) |
| Funding ID | 003/S/20 |
| Organisation | British Skin Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 03/2025 |
| Description | Multifunctionalized Microalgae - A novel and flexible platform technology for maximising feed/energy conversion ratios and treating severe infections in livestock. (Michael Allen) |
| Amount | £186,525 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2021 |
| Description | Muscle resilience across the life course: from cells to society |
| Amount | £184,485 (GBP) |
| Funding ID | BB/W018284/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2022 |
| End | 01/2024 |
| Description | NBIC Eurobiofilms Marketing funding |
| Amount | £6,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2019 |
| Description | NBIC Flexible Talent Mobility Account (FTMA) |
| Amount | £275,000 (GBP) |
| Funding ID | BB/S508020/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 02/2022 |
| Description | NIBB Summer Studentship Bursaries: Optimizing the operation of a novel photobioreactor (Mike Allen) |
| Amount | £2,500 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 07/2021 |
| Description | NanoPrime (Veeren Chauhan ) |
| Amount | £500 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2020 |
| End | 06/2020 |
| Description | NanoPrime (Veeren Chauhan ) |
| Amount | £2,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2019 |
| End | 06/2020 |
| Description | NanoPrime Rapid (Veeren Chauhan) |
| Amount | £5,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2021 |
| End | 08/2021 |
| Description | Nanoscale Characterisation of Biological and Bioinspired Materials using Integrated Fluidic Force - High-Resolution Confocal Microscopy |
| Amount | £777,904 (GBP) |
| Funding ID | BB/W019639/1 |
| Organisation | University of Nottingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2022 |
| End | 07/2023 |
| Description | Nanoscale Characterisation of Biological and Bioinspired Materials using Integrated Fluidic Force - High-Resolution Confocal Microscopy |
| Amount | £777,905 (GBP) |
| Funding ID | BB/W019639/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2022 |
| End | 07/2023 |
| Description | National Biofilms Innovation Centre |
| Amount | £12,801,513 (GBP) |
| Funding ID | BB/R012415/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 11/2022 |
| Description | National Biofilms Innovation Centre |
| Amount | £7,659,682 (GBP) |
| Funding ID | BB/X002950/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2022 |
| End | 11/2027 |
| Description | National Biofilms Innovation Centre NBIC 2021 Flexible Talent Mobility Account |
| Amount | £180,000 (GBP) |
| Funding ID | BB/W510865/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2021 |
| End | 03/2022 |
| Description | New Testing methods for Oral care (Yuri Diaz Fernandez) |
| Amount | £21,000 (GBP) |
| Organisation | Unilever |
| Sector | Private |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 12/2024 |
| Description | Newcastle University Impact Acceleration Account - Feasibility test for large scale Microbial Electrolysis Cells (MEC) with bespoke control unit (Elizabeth Heidrich) |
| Amount | £7,311 (GBP) |
| Organisation | Newcastle University |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 04/2023 |
| Description | Nottingham DTP3 |
| Amount | £14,883,260 (GBP) |
| Funding ID | BB/T008369/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 09/2028 |
| Description | Nottingham Research Fellowship (Veeren Chauhan ) |
| Amount | £300,000 (GBP) |
| Organisation | University of Nottingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2022 |
| Description | Novel Endolysin to Selectively Manage Antimicrobial Resistant S. aureus in Wound Biofilms |
| Amount | £101,356 (GBP) |
| Funding ID | CTP_22_0000000010 |
| Organisation | National Biofilms Innovation Centre |
| Sector | Private |
| Start | 01/2023 |
| End | 01/2027 |
| Description | Novel Raman Spectroscopic Analysis for In Situ Detection of AMR in Cystic Fibrosis |
| Amount | £15,000 (GBP) |
| Organisation | Southampton NIHR Biomedical Research Centre in Nutrition |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 10/2020 |
| Description | Novel rapid detection and imaging technologies for deep-sea applications |
| Amount | £120,000 (GBP) |
| Organisation | Japan Society for the Promotion of Science (JSPS) |
| Sector | Public |
| Country | Japan |
| Start | |
| Description | Partnership PhD (Robin Thorn) |
| Amount | £227,700 (GBP) |
| Organisation | Altered Carbon Ltd. |
| Sector | Private |
| Country | United Kingdom |
| Start | 09/2022 |
| End | 10/2025 |
| Description | PhD Antibiotic resistance and biofilm formation in the WHO priority pathogen Acinetobacter baumannii (Ronan McCarthy) |
| Amount | £84,048 (GBP) |
| Organisation | Brunel University London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 09/2025 |
| Description | PhD Control of Listeria monocytogenes in the fresh produce supply chain (Bill Keevil) |
| Amount | £120,000 (GBP) |
| Funding ID | 2597285 under BB/T008768/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2021 |
| End | 09/2025 |
| Description | PhD Developing ultrasound-responsive therapeutic agents for the treatment of chronic wounds (working title) (Dario Carugo) |
| Amount | £90,000 (GBP) |
| Organisation | University College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 10/2025 |
| Description | PhD Intraspecies competition mechanisms in Bacillus subtilis (Nicola Stanley Wall) |
| Amount | £85,236 (GBP) |
| Funding ID | 2734197 under BB/T00875X/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2022 |
| End | 09/2026 |
| Description | PhD Viscoelasticity and Associated-drag of Artificial and Natural Marine Fouling Biofilm (Jeremy Webb) |
| Amount | £111,500 (GBP) |
| Organisation | AkzoNobel |
| Sector | Private |
| Country | Netherlands |
| Start | 08/2019 |
| End | 09/2022 |
| Description | Pilot screen of selected compounds versus common Gram-positive and Gram-negative bacteria (Miguel Camara) |
| Amount | £11,689 (GBP) |
| Organisation | Eurofarma |
| Sector | Private |
| Country | Brazil |
| Start | 03/2019 |
| End | 07/2019 |
| Description | Plasma-activated antimicrobial hydrogel therapy (PAHT) for combatting infections in diabetic foot ulcers |
| Amount | £369,080 (GBP) |
| Funding ID | EP/V005839/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2021 |
| End | 01/2024 |
| Description | Product development award (PDA) scheme NIHR i4i: Can novel ureteric stents offer a better patient outcome compared to existing standard ureteric stents (CASSETTE) |
| Amount | £1,375,896 (GBP) |
| Funding ID | NIHR202935 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2022 |
| End | 01/2025 |
| Description | Project |
| Amount | £270,000 (GBP) |
| Organisation | The Dunhill Medical Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 09/2019 |
| Description | Proof of Concept application to the High Value Biorenewables Network (Eileen Yu) |
| Amount | £50,000 (GBP) |
| Funding ID | POC-HVB-2021/01 (YU) [University of York BBSRC High Value Biorenewables Network] |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 12/2022 |
| Description | Prophage host interactions: pulling back the curtains on Pseudomonas puppet masters (Heather Allison) |
| Amount | £901,000 (GBP) |
| Funding ID | BB/T015616/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2020 |
| End | 10/2023 |
| Description | Rapid characterisation and modelling of marine biofilm deformation for estimating biofouling frictional drag (Jinju Chen) |
| Amount | £86,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2022 |
| End | 09/2026 |
| Description | Rayleigh Light Sheet Microscopy for Label-free Chemical Imaging of DNA (impact Acceleration Account) |
| Amount | £50,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Research Fellowship : Identification of novel antibiofilm compounds using high throughput approaches. (Miguel Camara) |
| Amount | £63,749 (GBP) |
| Organisation | Alfonso Martin Escudero Foundation |
| Sector | Charity/Non Profit |
| Country | Spain |
| Start | 01/2020 |
| End | 07/2022 |
| Description | Research Fellowship : Role of signalling mechanisms in biofilms from uropathogenic E. coli (Miguel Camara) |
| Amount | £107,999 (GBP) |
| Organisation | Fundación Canaria de Investigación Sanitaria |
| Sector | Charity/Non Profit |
| Country | Spain |
| Start | 09/2019 |
| End | 04/2021 |
| Description | Royal Society University Research Fellowship |
| Amount | £1,119,000 (GBP) |
| Funding ID | URF\R1\221795 |
| Organisation | The Royal Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2022 |
| End | 09/2027 |
| Description | SUrfaCe Characteristics Enabled StrategieS against virus transmission (SUCCESS) |
| Amount | £649,501 (GBP) |
| Funding ID | EP/V029762/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 03/2022 |
| Description | Seeing the virus with topological optical microscopy |
| Amount | £180,022 (GBP) |
| Funding ID | BB/X003477/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2022 |
| End | 03/2024 |
| Description | Shape, shear, search & strife; mathematical models of bacteria |
| Amount | £361,730 (GBP) |
| Funding ID | EP/S033211/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 08/2023 |
| Description | South Coast Biosciences Doctoral Training Partnership (SoCoBio DTP) |
| Amount | £10,099,355 (GBP) |
| Funding ID | BB/T008768/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 09/2028 |
| Description | Southampton AMR Clinical Research Laboratory for Antimicrobial Resistance (AMR) Capital funding. (University of Southampton, Jeremy Webb, NIHR200638) |
| Amount | £2,859,674 (GBP) |
| Funding ID | NIHR200638 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 10/2021 |
| Description | Southampton NIHR Biomedical Research Centre |
| Amount | £25,000,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2022 |
| End | 11/2027 |
| Description | StarHealer: a novel ultrasonically activated water stream device for wound management (Bill Keevil) |
| Amount | £32,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2018 |
| Description | Strategic Research Centre: An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). |
| Amount | £773,682 (GBP) |
| Funding ID | SRC022 |
| Organisation | Cystic Fibrosis Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 03/2026 |
| Description | Strength in Places Fund: Delivering Integrated Solutions for Human Infections. (Rasmita Raval) |
| Amount | £18,000,000 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 08/2025 |
| Description | Studying embryo development by novel microscopy techniques for improving IVF screening (PhD studentship) |
| Amount | £40,000 (GBP) |
| Funding ID | 2155568 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 06/2022 |
| Description | The Physics of Antimicrobial Resistance |
| Amount | £2,158,027 (GBP) |
| Funding ID | EP/T002778/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 09/2022 |
| Description | The Physics of Bacteriophage-coated Antimicrobial Surfaces |
| Amount | £613,277 (GBP) |
| Funding ID | EP/S001255/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 09/2022 |
| Description | The State Key Laboratory Program: Understanding polybacterial interactions during rice disease (Shi-qi An) |
| Amount | £11,000 (GBP) |
| Organisation | Guangxi University |
| Department | State Key Lab for Conservation and Utilization of Subtropical Agro bioresource |
| Sector | Academic/University |
| Country | China |
| Start | 12/2018 |
| End | 12/2020 |
| Description | The Sustainable Innovation Fund: Optically enhanced antiviral transparent screen protection |
| Amount | £235,709 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 06/2021 |
| Description | The Sustainable Innovation Fund: round 1 (temporary framework) |
| Amount | £192,206 (GBP) |
| Funding ID | 77477 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 06/2021 |
| Description | The association of biofilms to water quality deterioration in Valencia (The University of Sheffield, Isabel Doutelero) |
| Amount | € 21,000 (EUR) |
| Organisation | Global Omnium |
| Sector | Private |
| Country | Spain |
| Start | 09/2019 |
| End | 10/2020 |
| Description | Transformative Imaging for Quantitative Biology (TIQBio) Partnership |
| Amount | £1,626,518 (GBP) |
| Funding ID | EP/V038036/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 03/2027 |
| Description | Transforming industry standards in healthcare: Connecting key UK interdisciplinary analytical platforms for biofilms across the NBIC, NPL, SCELSE and SNBC (Paulina Rakowska) |
| Amount | £200,000 (GBP) |
| Organisation | Department for Business, Energy & Industrial Strategy |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2021 |
| End | 03/2021 |
| Description | Treatment of recurrent bacterial vaginosis using engineered probiotic bacteria |
| Amount | £612,881 (GBP) |
| Funding ID | BMC 10035355 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 02/2025 |
| Description | UKRI Ideas to address COVID-19 - Innovate UK Temp F'work Aug 2020 (University of Edinburgh, Rosalind Allen and Susana Direito, 83701) |
| Amount | £519,283 (GBP) |
| Funding ID | 83701 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2020 |
| End | 02/2022 |
| Description | UKRI Interdisciplinary Centre for Circular Chemical Economy (Loughborough University, Eileen Yu) |
| Amount | £4,436,401 (GBP) |
| Funding ID | EP/V011863/1 |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2021 |
| End | 12/2024 |
| Description | UVC-pulsed Lasers for Rapid Disinfection of Pathogen (Impact Acceleration Account) |
| Amount | £20,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 12/2021 |
| Description | Understanding inter-kingdom and inter-microbial interactions in microbial and fungal communities - Nanoprime (University of Nottingham, Shaun Robertson) |
| Amount | £14,880 (GBP) |
| Organisation | University of Nottingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 11/2019 |
| Description | Understanding interactions between microbes in polymicrobial communities via liquid extraction surface analysis (LESA) mass spectrometry - British Mass Spectrometry Society (University of Nottingham, Shaun Robertson) |
| Amount | £4,160 (GBP) |
| Organisation | British Mass Spectrometry Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2019 |
| Description | Understanding the impact on underwater cleaning on fouling control coatings (Jinju Chen) |
| Amount | £104,900 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2023 |
| End | 09/2027 |
| Description | Understanding the molecular survival strategies of Acinetobacter baumannii and developing strategies to disable them. |
| Amount | £451,305 (GBP) |
| Funding ID | BB/V007823/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2021 |
| End | 03/2024 |
| Description | Unravelling the quorum sensing mechanisms in Azospirillum brasiliense Az39: one of the most used strains for agriculture in America (Miguel Camara) |
| Amount | £12,000 (GBP) |
| Funding ID | IEC\R2\181079 |
| Organisation | The Royal Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2018 |
| End | 12/2021 |
| Description | Wellcome Prime Covid-19 Research Support (Shaun Robertson) |
| Amount | £10,306 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2022 |
| End | 12/2022 |
| Description | Wellcome Prime Scholarship (Veeren Chauhan) |
| Amount | £5,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2021 |
| End | 07/2022 |
| Title | A surface-confined liposome system for early-stage evaluation of new antimicrobial molecules (Peng Bao) |
| Description | Many antimicrobial molecules work by disrupting cell membranes. There have been a few well-established systems/protocols for evaluation of this mode of action at the early stage of technology development. In particular, there is a need for a fast and sensitive evaluation of such ability directly at a surface. Here, we developed an assay that allows fast screening of a wide range of antimicrobial agents. A fluorescent leakage assay employing surface-confined liposomes could provide a fast/sensitive platform for the evaluation of new antimicrobial molecules. The antimicrobial properties of UV-powered active molecules (provided by our partner at the University of Nottingham) were tested using a surface-confined liposome leakage assay in vitro. The leakage assay employed micro-sized DOPC/DOTAP (1:1) vesicles attached to the glass surface and checked under UV exposure from the LED light source on Zeiss Image2 fluorescence microscope. The mean time constants (averaged over many individual vesicles, n>20) were found to be distinctly different for samples with and without molecules, directly demonstrating the disruptive effect of molecules on lipid membranes. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2022 |
| Provided To Others? | No |
| Impact | The surface-confined liposome system provides an easy, fast, and sensitive way for the early-stage evaluation of the potential of new active molecules for antimicrobial applications. It could find wide applications in drug screening. |
| Title | Automated in-situ biofilm imaging and mechanical characterisation (Jinju Chen) |
| Description | We developed a uniquely designed automated in-situ testing rig to detect and monitor of marine biofilm erosion and study marine biofilm mechanical properties at meter scale. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2020 |
| Provided To Others? | No |
| Impact | This technique enabled the new partnership with International Paint (AkzoNobel). We are in the process of applying the patent. |
| Title | CSF derived Biomarker for Alzheimer's |
| Description | Novel biomaker for diagnosing AD when combined with core biomarkers and imaging |
| Type Of Material | Physiological assessment or outcome measure |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | No impact yet. |
| Title | Developed casting methods for creating elastomeric replicas of rigid structured surfaces with micron-level accuracy (Paul Stoodley) |
| Description | The research tool is a pipeline from casting real surface roughness from materials, including marine fouled surfaces, and creating materials with replicated patters and roughness with defined viscoelastic parameters in able to assess the relative influence of material viscoelasticity and roughness on marine drag. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2020 |
| Provided To Others? | No |
| Impact | The data generated are currently being prepared for a manuscript and will serve as a PhD thesis chapter. |
| Title | Endoscope biofilm model. (Robin Thorn) |
| Description | UWE developed an Endoscope Biofilm Model, comprising of a re-circulating perfusion system with a known microbial load through a surrogate endoscope operating channel (PTFE tubing). The biofilm densities of the test bacterial species were determined following 72 hours of culture within the EBM. Viable biofilms were recovered from the EBM for all four bacterial species tested; P. aeruginosa, S. aureus, K. pneumonia and E. coli, whereby the results demonstrated the growth of reproducible biofilms. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2020 |
| Provided To Others? | No |
| Impact | The development of this model has led to the successful demonstrated pf the efficacy of a Creo Medical Ltd. developed endoscope disinfection system for the treatment of bacterial biofilms within the internal lumen of PTFE tubing as a surrogate for medical endoscope operating channels. The success of this approach has led to successful follow-on funding directly from Creo Medical Ltd. |
| Title | Ex vivo lung model - optimised / UKAS-accredited implementation (Freya Harrison) |
| Description | In line with the aims of the grant, we have optimised and shared our ex vivo lung model. The current grant has allowed significant improvements and flexible re-optimisation of the model to make it more useful and tractable for colleagues, especially those in industry. We have successfully trained scientists from Perfectus Biomed Ltd. in the use of the model and helped them gain UKAS accreditation for its use in preclinical testing of antibiofilm agents. We have also published and open-access protocol for use of the model in antibiotic susceptibility testing (JoVE, video protocol to follow - delayed by COVID-19 restrictions). Please also refer to other sections of the ResearchFish submission for details of ongoing use and uptake, and the dedicated website at https://warwick.ac.uk/fac/sci/lifesci/people/fharrison/exvivolung. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| Impact | Accreditation of the model and Standard EN 1276 to ISO 17025 by our industrial collaborator Perfectus Biomed Ltd. for biocide testing on biofilms of P. aeruginosa. Now beiing used by Perfectus Biomoed Ltd. to test candidate antibiofilm agents for industrial clients. See https://perfectusbiomed.com/perfectus-biomed-elevate-method-testing-beyond-the-standard/ We have also published an open-access protocol for use of the model in antibiotic susceptibility testing for P. aeruginosa and S. aureus in JoVE (see Publications). We will continually monitor uptake of the model through the lifetime of the grant and beyond, an in particular record any concomitant reduction in animal usage by users of the model, and report on this at a later stage. |
| URL | https://www.jove.com/t/62187/antibiotic-efficacy-testing-an-ex-vivo-model-pseudomonas-aeruginosa |
| Title | Fabrication of novel antimicrobial membrane to remove biofilm in female reproductive system (Farshid Sefat) |
| Description | In this research a group of scaffolds encapsulated and fabricated with a antibacterial drug and tested biologically. This scaffold remove biofilm in female reproductive system by a novel method. |
| Type Of Material | Biological samples |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | This is an ongoing experimental work and we are predicting the outcome will have significant impact on many patients who suffering from bacterial within females reproductive system. |
| Title | Image analysis protocol for quantifying surface structural deformation under hydrodynamic shear. (Paul Stoodley) |
| Description | Developed image analysis protocol for quantifying surface structural deformation under hydrodynamic shear from cross sectional optical coherence tomography images of the elastomeric replica surfaces. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2020 |
| Provided To Others? | No |
| Impact | These data will be used in a peer reviewed manuscript and as a PhD chapter. |
| Title | Improvement of self referencing method for recording and mapping both ion and molecular activity and flux from single cells, tissues and biofilms (Peter J. Smith) |
| Description | Further development of the self referencing electrochemical method for detection of chemical activity or flux from living systems with high temporal and spatial fidelity. Previous a bespoke system the design brings in commercially available equipment, modified for function, and delivering higher sensitivity, control, analytics and versatility. Parllel and ongoing evolution of the solid state ultra micro sensor designs provide a more robust base for distributing the technology. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| Impact | Van Mooy, B.A.S., Hmelo, L.R., Fredricks, H.F., Ossolinski, J.E., Pedlera, B.E., Bogorff D.J. and Smith P.J.S. (2014) Quantitative exploration of the contribution of settlement, growth, dispersal and grazing to the accumulation of natural marine biofilms on antifouling and fouling-release coatings. Biofouling 30(2):223-236. DOI: 10.1080/08927014.2013.861422. Alavian, KN, Collis, L, Li, H, Bonanni, L, Zeng, L, Sacchetti, S, Lazrove, E, Nabili, P, Flaherty, B, Graham, M, Chen, Y, Messerli, S, Mariggio, MM, Rahner, C, McNay, E, Shore, G, Smith, PJS, Hardwick, JM and Jonas, EA 2011 Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase. Nature Cell Biol. 13, 1224-1233 doi:10.1038/ncb2330. |
| URL | https://www.tandfonline.com/doi/full/10.1080/08927014.2013.861422 |
| Title | Method to measure natural marine biofilm accumulation on artifical surfaces (Karen Tait) |
| Description | During this project we have made adaptions to established epifluorescence microscopy methods to allow us to measure natural microbial biofilm accumulation on artificial surfaces that have been exposed to untreated natural seawater. We have used epifluorescence techniques combined with image analysis to increase through-put and quality control associated with data capture from multiple images. This revised method will form the basis of a commercial biofilm quantification service and as such is commercially sensitive. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2020 |
| Provided To Others? | No |
| Impact | We anticipate that this method will form the basis of a commercial biofilm quantification service for PML. |
| Title | Microfluidic-based models to screen formation of crystalline biofilms in urological devices (Dario Carugo) |
| Description | Microfluidic devices (referred to as stent-on-a-chip, SoC) were designed to replicate key flow dynamic features of a stented ureter in the presence of different types of ureteral obstruction. Dimensions mimic those of commercially available double-J stents. A replica moulding technique was employed in order to manufacture SoC devices, which employed 3D printed polylactic acid (PLA) master moulds. Devices can replicate the architecture of different urological stents and patient-specific urinary tracts. They have been employed as an in-vitro model to iterate different urological stent designs and assess whether specific device geometries could minimise deposition of bacteria over the device surface. |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | Novel ureteric stent designs have been developed, which have been proven to reduce particle deposition in-vitro. See following publications and patents: (1) Particle Accumulation in Ureteral Stents Is Governed by Fluid Dynamics: In Vitro Study Using a Stent-on-Chip Model (2) Reducing deposition of encrustation in ureteric stents by changing the stent architecture: A microfluidic-based investigation (3) A Microfluidic-Based Investigation of Bacterial Attachment in Ureteral Stents (* directly linked to this award) (4) Stent With Streamlined Side Holes |
| URL | https://www.mdpi.com/2072-666X/11/4/408/htm |
| Title | Model reactor and culture system for biofilm metrology studies. |
| Description | We have developed a CDC reactor model system for Pseudomonas aeruginosa culture in order to carry out studies of biofilm reproducibility in partnership with LGC. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2022 |
| Provided To Others? | No |
| Impact | Knowledge exchange and collaborative work in the area of biofilm metrology with industry partner LGC. |
| Title | Model system for the assessment of in-line ozone treatment in drinking water pipelines. |
| Description | Oxi-Tech have developed an in-line system for the delivery of ozone as a method to treat bacteria and biofilms within drinking water systems. We developed a recirculating water model system that incorporated an Oxi-cell and that was used to model water contamination by planktonic bacteria Escherichia coli, P. aeruginosa, and Legionella shakespearei. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2022 |
| Provided To Others? | No |
| Impact | The Oxi-cell eradicated planktonic bacteria following 10 mins of activity. Biofilms of P. aeruginosa and L. shakespearei were grown for 48h and transferred to a model water system that contained 15m pipe between the Oxi-cell and the biofilms. Oxi-cell activity significantly reduced the percentage of live cells in L. shakespearei biofilms from 78% to 42%, and prevented the dispersal of live cells from the biofilms. These data together suggest that the Oxi-cell is effective at preventing dissemination and growth of bacterial biofilms within water systems, where it is unable to eradicate established biofilms. |
| Title | Optical imaging of wound dressings (Daimark Bennett) |
| Description | Development of an approach to visualise wound dressings and associated microbial biofilms using confocal microscopy. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | In preparation. |
| Title | Partial development of a novel testing rig (Karen Tait) |
| Description | This project has been severally impacted by Covid-19 and as such is still in its very early stages. We are in the early stages of developing a novel laboratory test rig to allow us to remotely quantify marine biofouling on a test panel. Due to the commercial interest in the project and IP agreements in place with our funders (National Biofilm Innovation Centre) it is not possible to disclose further information concerning the biofilm quantification techniques. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2020 |
| Provided To Others? | No |
| Impact | None yet. |
| Title | Polymicrobial biofilm development |
| Description | This tool is a complex wound biofilm that can be used to assess inflammation and the effects of antimicrobials. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | Facilitated the methods to secure EPSRC grant |
| URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991182/ |
| Title | Porcine corneal explant cultures for antimicrobial drug development (Peter Monk) |
| Description | The corneum is a complex multi-layered tissue that is not easy to reproduce using cell lines. To avoid the use of living animals, we have developed an ex vivo model using the easily available by-product of the food industry. Infection with bacteria or fungi requires abrasion of the corneal epithelial layer, usually a requirement in vivo. Infection of the explants recapitulates infection in vivo, and appears similar to that seen in human corneal explants. |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Year Produced | 2019 |
| Provided To Others? | No |
| Impact | We will shortly be creating a video methods publication to allow other groups to use this method. |
| Title | Porcine skin explant model of infection using Staphylococcus aureus and Pseudomonas aeruginosa |
| Description | The skin explant model developed for this project a. allowed us to evaluate antimicrobial drug efficacy against biofilm infection. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2021 |
| Provided To Others? | Yes |
| Impact | The model allowed us to assess Destiny Pharma's novel antimicrobial compound for efficacy against biofilm-associated infection - the compound was highly effective at killing biofilms formed by clinical S. aureus strains in the pig skin explant model. |
| Title | Rapid single-step fluorescence detection using aptamer beacon (Sourav Ghosh) |
| Description | The assay involves an aptamer beacon, which acts like a fluorescence switch. The aptamer fluorescence is turned off in its original state. In presence of the target species, the aptamer undergoes a change in configuration, which turns on the fluorescence. The change in intensity of fluorescence suggests quantitative detection of the target species. The method is application to a broad range of biomolecules (proteins, lipid, carbohydrates) and biological particles (fungus, spores, bacteria and virus). |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | Success validation has led to clinical evaluation projects in point of care wound diagnosis (from wound swabs) and COVID-19 diagnosis from saliva. |
| Title | Reagents to monitor biofilm assays in vivo in C. elegans |
| Description | Reagents to monitor biofilm assays in vivo in C. elegans tested and validated. Work to improve reagents and methods ongoing in the lab. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | None yet but work is continued to achieve impact. |
| Title | Rotating Spiral Bioreactor (Jordan MacInnes) |
| Description | The prototype reactor developed in the project allows interaction between beds of microbial particles and media solutions in a controlled and therefore tractable manner. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | The device has already allowed precise investigation of reaction rates in microbial particle beds as a function of microbial type. The same will be true for catalytic particles of any kind. |
| Title | Standard method for growing simulated dental plaque biofilms for safety and efficacy testing using modifications of CDC and ASTM standard methods (Paul Stoodley) |
| Description | Biofilm communities grown from human saliva on hydroxyapatite coupons in the CDC reactor were identified through 16S sequencing and included the presence of key taxa including Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and Fusobacteria which form the healthy core oral microbiome, including aerobes, anaerobes and unculturable species. Over an 8 day time course we observe changes to the composition of the microbiomes within the model bioreactor systems. To test this hypothesis, we utilized the commonly used antimicrobial compound chlorhexidine. Chlorhexidine was applied to bioreactor biofilms for 2 weeks resulting in significant differences in taxa composition compared to both the Control treatment and . These observations indicate that the model developed is a suitable tool for the investigation of the oral microbiome and may be valuable in determining the impact of active compounds and antimicrobial technologies on the oral microbiome, facilitating the improved development of oral healthcare products. A publication is in preparation. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2020 |
| Provided To Others? | No |
| Impact | The method has potential for adoption by dental companies for testing dental hygiene products in vitro. |
| Title | The UK CF Infection Biorepository (UKCFIB) |
| Description | THE UKCFIB addresses a key challenge in CF antimicrobial discovery and development: the difficulty researchers face to access all the sample types required for preclinical testing. Coordinated by the MDC, the UKCFIB brings together a network of eight Universities and Hospitals, each linked to an NHS specialist CF centre that holds clinics for adults and children with CF. Initially funded by the Trust and Antabio, the UKCFIB has been awarded further funding from the Cystic Fibrosis Foundation, which will start in October 2022 to further develop the initiative. The UKCFIB supports innovators to access hard-to-access samples, data and expertise, speeding up their drug discovery programmes. |
| Type Of Material | Biological samples |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | Access to high quality clinically relevant samples, data and expertise will enable researchers from academia and industry to quickly identify and translate discoveries into new treatments for infections in people with cystic fibrosis. |
| URL | https://cfamr.org.uk/uk-cf-infection-biorepository/ |
| Title | Use of HS-AFM as a tool for biofilm monitoring (Michael Allen) |
| Description | High Speed Atomic Force Microscopy was successfully developed as a tool for assaying and analysing the structural features of biofilms. Various solid substrata which could be used in membrane bioreactors were assayed including isotactic polypropylene, polypropylene, polyethylene, polyamide and polystyrene. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2019 |
| Provided To Others? | No |
| Impact | Following incubation in an aqueous environment, we could confirm and monitor biofilm formation with nanoscale resolution.Indeed, in addition to whole cellular observations ranging from larger microalgal diatom cells and bacteria, we could successfully observe what we believe to extracellular polysaccharide coating plastic surfaces. This was achieved in both air and liquid environments, the latter in particular raising the possibility of utilising this technique for non-destructive assessment of biofilm formation in the future. Independent software developments during the course of this project have allowed for the real time stitching of raster pattern generated images, providing SEM scale imagery, but delivering nanoscale resolution.Following the successful trial of the MMBR system, biofilms were monitored with the new SOP developed herein, providing HS-AFM data showing colonisation of the 'mesh' utilised. Interestingly, cells were observed to adhere to the surface elements of the individual membrane fibres, as well as being corralled in to the intervening spaces of the structure. Further work could determine the rate of colonisation and how repeated harvesting effects biofilm structure, function and integrity. |
| Title | Using H-NMR to detect the generation of Reactive Oxygen Species (Claudio Lourenco) |
| Description | This technique consists in the use of H-NMR to follow the reactions taking place within a complex formulation with particular emphasis in the generation of ROS. On its own the technique can effectively detect and quantify the elements present in the mixture. By fine tuning the pH of the environment the generation of ROS can be increased and its half-life in solution increased. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | The main impact is that it allows a quick screening and quantification of a complex mixture of ingredients within a solution. It can be extremely valuable to compare new formulations enabling the researcher to test the reactants efficacy in the early stages of product development saving costs and time on not so good formulations. |
| Title | Viability status: inability of viability kits to assess damage from ozone-treated Listeria monocytogenes (Nicola Holden) |
| Description | Qualitative assessment of Listeria monocytogenes (Lmo) viability in biofilms was made with Lmo biofilms stained with the commercial LIVE/DEAD BacLight kit and imaged by microscopy, mounted on polylysine-coated slides. Initially, an in vitro test was performed with a 1:1 mixture of Lmo killed with 70% isopropyl alcohol: live cells cultured in TSB, and it was possible to detect both live and dead cells at the proportions expected. Detailed examination of the slides using con-focal microscopy showed two distinct layers of Lmo cells. To investigate this phenomenon, the Lmo cells were co-stained with another nuclei acid stain DAPI, and a membrane stain (FM 1-43). There appeared to be two types of debris: one stained with SYTO9 and close to the coverslip and another stained with DAPI and close to the microscope slide. The DAPI-stained debris near the slide associated with the membrane dye (FM 1-43), suggesting that lipids that may have altered the density or adhesive properties of DAPI. It is possible that staining with SYTO9 may competitively prevent binding of DAPI, explaining why it wasn't uniform. Live/Dead staining was then performed on Lmo biofilms in situ on stainless steel (SS) discs, +/- ozone treatment. It appeared that the ozone-treatment had a minimal effect on cell viability since only a very low proportion of Lmo were stained with propidium iodide in comparison to untreated SS disc biofilms that contained a 'natural' population of dead cells. Therefore, the stains were validated in situ by treatment of Lmo on SS discs with 70 % isopropyl alcohol for 1 hour, which resulted in a high proportion of dead cells, as expected. However, treatment with 3 % hydrogen peroxide for 30 minutes only yielded a small proportion of dead cells. Yet, Lmo viable plate counts decreased by ~ 2 orders of magnitude after treatment with just 2000 ppm (0.2 %). Therefore, there was a large discrepancy in viability as reported by the Live/Dead staining kit for peroxide or ozone treatments compared to viability as assessed by CFU. It was apparent that the PI dye was not able to enter ozone/peroxide-treated cells. |
| Type Of Material | Physiological assessment or outcome measure |
| Year Produced | 2019 |
| Provided To Others? | No |
| Impact | The main outcome is that we are now much better informed on whether commercial kits provide correct answers to quantify viable cells and we know that it is not possible to use this approach to assess viability of ozone or peroxide-treated biofilms. Although the kits work well for other physiological stresses that result in cell death / reduced viability, the one we tested (most commonly used) was unable to accurately quantify viability from ozone or H2O2 treated cells. This has implications for food safety risk assessments since reactive oxygen (in various forms) is used commercially as a bactericidal agent. Our data was accumulated from an experimental set-up that reflected Listeria contamination in food processing settings, i.e. at low temperature and allowing biofilm formation to occur on stainless steel surfaces. We show that if the commercial kits are used for quantification of viability, and hence to calculate the extent of die-off following treatment, they would not be accurate and could over-estimate the extent of kill / die-off. In turn, this would provide mis-leading information on the efficacy of the treatment in food safety settings. |
| Title | Workflow for genomic assessment of microbially influenced corrosion |
| Description | The team have developed expertise in field based DNA sequencing and the use of the Nanopore sequencing platform for energy sector samples. Furthermore, the secondment has facilitate the development of industry links, both in the UK and internationally through DNV GL's global research team. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2023 |
| Provided To Others? | No |
| Impact | The FTMA application has allowed knowledge exchange between NBIC researchers and renewable energy industries and infrastructure that will be required for the energy transition. This has involved working with DNV who provide access to bacterial corrosion samples, and have assets such as wind farms and pipeline digs and are who are familiar with the industries standardisation processes. |
| Title | YouSeq The ONE 16S NGS kit |
| Description | Create a ready to sequence 16S Library in one closed tube reaction. The ONE 16S NGS kit contains all of the reagents necessary to create a ready-to-sequence NGS library in minutes. In a breakthrough kit format, the user simply performs one closed tube qPCR reaction. The variable regions V3/4 are targeted, amplified and adapters are added in a single reaction. The quantitative PCR read out simultaneously quantifies each library so they can be pooled precisely. Then a simple bead-clean completes the workflow. After sequencing, the data can then be loaded on to our cloud for rapid analysis. A detailed report is typically returned within 15 minutes. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2019 |
| Provided To Others? | Yes |
| Impact | This product was developed during an NBIC funded secondment. |
| URL | https://youseq.com/product/the-one-16s-ngs-kit/8 |
| Title | CSD 1977978: Experimental Crystal Structure Determination |
| Description | Related Article: Quinn D. Gibson, Troy D. Manning, Marco Zanella, Tianqi Zhao, Philip A. E. Murgatroyd, Craig M. Robertson, Leanne A. H. Jones, Fiona McBride, Rasmita Raval, Furio Cora, Ben Slater, John B. Claridge, Vin R. Dhanak, Matthew S. Dyer, Jonathan Alaria, Matthew J. Rosseinsky|2020|J.Am.Chem.Soc.|142|847|doi:10.1021/jacs.9b09411 |
| Type Of Material | Database/Collection of data |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| URL | http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.25505/fiz.icsd.cc24d7rk&sid=DataCite |
| Title | Dataset in support of the Southampton doctoral thesis 'Layer by layer (LbL) coating on urological devices to prevent biofilm formation |
| Description | The dataset contains Nanoindentation results for coated and uncoated samples of PDMS with PEI/PAA multilayers. The number of bilayers of PEI/PAA coating varies from 5-50 and the stiffness of the surface compared with uncoated PDMS in different indentation depths. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | Nanoindentation data provides information about surface stiffness, which correlates with antimicrobial (AM) activity of coated surfaces and helps establish a potential AM mechanism that is disputed or not fully understood in the field. |
| URL | https://eprints.soton.ac.uk/472184/ |
| Title | Experimental model for pre-clinical screening of urological devices (Dario Carugo) |
| Description | The research model comprises a microfluidic-based mimic of the stented proximal urinary tract, which can be integrated with optical/fluorescence microscopy to determine the spatio-temporal evolution of encrustation in urological devices during product development. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| Impact | Models could be potentially employed as an alternative to animal models, in the process of iteration and pre-clinical assessment of innovative ureteric stent designs. It specifically enables investigation of the effect of urinary flow dynamics, stent's architecture, and material properties on the initiation of bacteria/crystal deposition and biofilm formation. |
| URL | https://www.mdpi.com/2072-666X/11/4/408 |
| Title | Grant data from 01POC18027 (Samantha McLean) |
| Description | Data arising from the PoC grant, raw data files have been uploaded to Zenodo.org. This is a closed dataset until publication, at which time it will be published in accordance with the journal requirements. Access to this data can be requested by contacting samantha.mclean@ntu.ac.uk. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | N/A |
| Title | Model for reaction in a rotating spiral bioreactor (Jordan MacInnes) |
| Description | The mathematical model provides a consistent detailed representation of the mass transfer and reaction within a microbial bed in a rotating spiral channel. The model allows rapid determination of optimum reactor operation once a small number of bed properties are determined empirically. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | We are currently using the model to understand optimisation of catalytic particle reaction in our prototype spiral bioreactor. |
| Title | National Biofilms Innovation Centre Data and Resource Index |
| Description | Most Universities within the NBIC consortium already have large data storage facilities and the capacity to assign unique and permanent Digital Object Identifiers. The NBIC Universities will provide mechanisms and services for storage, backup, registration, deposit, retention and preservation of research data assets in support of current and future access, during and after completion of research projects. All NBIC partners will be required to agree to store all data, whether published or unpublished, in their institutional repositories or authorised storage facilities. NBIC are in a unique position to create data sharing policies and workflows for biofilm data. Metadata records for the data (and published outputs) generated by the consortium will be maintained by NBIC. In accordance with this, the data will be archived from a minimum of ten years after publication or last access, whichever is longer. This register includes reference to the relevant DOIs and points of contact to ensure data access is easily managed. Data will be accompanied by contextual information to enable secondary users to gain access to details on the origin or manipulation of the data to avoid misinterpretation or misuse. Future users of the data will be bound by data sharing agreements. Where suitable a licence (for example Creative Commons) can be applied to data deposited in the repository. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2019 |
| Provided To Others? | Yes |
| Impact | We are continuing to develop a cultural shift towards ensuring the availability of unpublished data across the NBIC consortium. We have held a workshop on data and software sustainability and are moving towards developing a community platform available to all partners. https://www.software.ac.uk/blog/2019-12-16-2019-national-biofilms-innovation-centre-workshop |
| Title | OM model development (Angela Oates) |
| Description | 1. Development and Validation of Osteomyelitis Biofilm Infection Model-stable and reproducible growth of S.aureus biofilm on HA discs 2. Optimisation of porous bone cement-rations of carboxymethyl cellulose (CMC) gel and smartset bone cement to generate porous bone barriers |
| Type Of Material | Database/Collection of data |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | Development of static model which stimulated porous bone in osteo enabled the exploration of plasma penetration through this barrier and measure its efficacy against propergated biofilms. Parameters of plasma doing could then be optimised. |
| Title | PlasmaTec Plasma testing data (Angela Oates) |
| Description | Viable count data or zone of inhibition size on s. aureus planktonic and biofilm populations 1.Treatment Time and Flow Rate Parameter Testing on Planktonic Populations-s. aureus 1,3 and 5 mins at 15w and flow 5slm 2. Flow rate optimisation -1cm distance 15w power settings 300s treatment-2.5,3.7,5 slm flow rate 3. PlasmaTec testing against Colony biofilms-biofilm age 1hr, 2hr, 4hr,6hr and 24hr 4. Hydroxyapatite Disk Biofilms Direct Dosing-biofilm age 2,4,6and24hr treated for 300s 15w, 5slm flow at 1cm distance 5. Hydroxyapatite Disk Biofilms Direct Dosing. pulses of 1min for a treatment of 5 mins 6. Treatment Time and Flow Rate Parameter Testing on Planktonic Populations (5cm distance) 7. Temperature evaluation |
| Type Of Material | Database/Collection of data |
| Year Produced | 2020 |
| Provided To Others? | No |
| Impact | Evaluation of the efficacy of plasma from the device and identification of temperature effect. |
| Title | Raw sequence data: Influence of phosphate dosing on biofilms development on lead in chlorinated drinking water bioreactors (Isabel Doutelero) |
| Description | Raw sequence data that support the findings of this study have been deposited in NCBI library as a Sequence Read Archive (SRA) with the accession code PRJNA663268 (https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA663268). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2019 |
| Provided To Others? | Yes |
| Impact | Better understanding of the practice of phosphate dosing for water companies in the UK. |
| URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585443/ |
| Title | Steriplas Penetration and Efficacy Plasma in the OM Biofilm Infection Model and Bone (Angela Oates) |
| Description | Viable counts 1. Penetration and Efficacy Plasma in the OM Biofilm Infection Model-24hr biofilms + porous bone cement. Plasma dosing occurred at 24hr (10 minutes) which was repeated after 2hr. single v double dosing 2.Temperature changes in response to plasma -evaluation of additional parameter to assess if this is contributing to effect seen 3.Demonstration of Plasma Penetration Through Porous Bone Cement-comparison between porous bone cement, bone cement and plastic barrier 4.Preliminary Testing of the Efficacy of Plasma Treatment on Osteomyelitis Biofilms-Bone used in place of porous bone cement barrier in OM infection model 5. Preliminary Testing of the Efficacy of Plasma Treatment on Osteomyelitis Biofilms-Drilled bone used in place of porous bone cement barrier in OM infection model |
| Type Of Material | Database/Collection of data |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | Understanding of of the role biological mater in plasma penetration and efficacy. |
| Title | Steriplas Plasma doing optimisation (Angela Oates) |
| Description | Viable counts of 1. Effect of Plasma on Planktonic Populations and Hydroxyapatite Biofilms using current treatment settings-against 0hr, 5hr and 24hr biofilms 2.Evaluation of the frequency of Treatment: 10 Minute Dosing vs Multiple Dosing against 24hr biofilms. (1) single dose: 10 minutes plasma dosing at 24hrs, (2) Double dose: 10 minutes plasma dosing at 24hrs, repeated 2 hours later and (3) Triple dose: 10 minutes plasma dosing at 24hrs, repeated 2hr and 4hr. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | Optimisation of dosing strategy to be testing in model and bone. Data shared with partner company. |
| Title | Wound biofilm volatile compound database (Robin Thorn) |
| Description | The project has resulted in the generation of data sets related to the development of the sensor response of the Altered Carbon sensor array to key microbial volatiles emanating from wound biofilms. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2020 |
| Provided To Others? | No |
| Impact | This proof-of-concept study has resulted in identification of a suitable Altered Carbon graphene sensor array, that with further refinement and tuning has the potential to lead to development of a sensor array capable of discriminating between P. aeruginosa, S. aureus and S. pyogenes biofilms and sterile control samples. This work lays the foundation for development of a sensor system that can be applied to identification of these bacterial species in a clinical setting, and funding is now being sought to exploit these study findings. |
| Description | 20ALERT Live 3D Confocal Imaging in real time with high throughput, multipoint, targeted acquisition and AI-assisted quantification (Kim Hardie and Miguel Camara) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | BBSRC funding reference BB/V019414/1. |
| Collaborator Contribution | Joint funding. |
| Impact | Capabilities in cell, tissue and material engineering and bioprinting in 2D and 3D require next level analytical platforms. These span the length-scales of macro- (cell behaviours, physical attributes) to micro- and nano-scale. The latter includes protein crystallisation and high field NMR optimised for challenging systems (proteins / RNA / lipids etc). Our systems have capabilities such as high sensitivity cryogenically cooled probes, solid-state magic angle spinning (Ultrafast spinning upto 65 KHz), reaction monitoring and automaton for screening. |
| Start Year | 2021 |
| Description | 20ALERT Live 3D Confocal Imaging in real time with high throughput, multipoint, targeted acquisition and AI-assisted quantification (Kim Hardie and Miguel Camara) |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | BBSRC funding reference BB/V019414/1. |
| Collaborator Contribution | Joint funding. |
| Impact | Capabilities in cell, tissue and material engineering and bioprinting in 2D and 3D require next level analytical platforms. These span the length-scales of macro- (cell behaviours, physical attributes) to micro- and nano-scale. The latter includes protein crystallisation and high field NMR optimised for challenging systems (proteins / RNA / lipids etc). Our systems have capabilities such as high sensitivity cryogenically cooled probes, solid-state magic angle spinning (Ultrafast spinning upto 65 KHz), reaction monitoring and automaton for screening. |
| Start Year | 2021 |
| Description | 3M collaborative research project (Miguel Camara) |
| Organisation | 3M |
| Country | United States |
| Sector | Private |
| PI Contribution | Confidential |
| Collaborator Contribution | Confidential |
| Impact | Ongoing research |
| Start Year | 2018 |
| Description | A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens (Miguel Camara) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | This award will allow us to establish a new synergistic partnership between the UK's National Biofilm Innovation Centre (NBIC) and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) in Ghana. Biofilms are implicated in some of the most critical global challenges and have significant economic impact across multiple sectors. They are a leading cause of chronic infections and antimicrobial resistance (AMR), described in June 2021 by G7 Health Ministers as a "silent pandemic"1 and the cause of at least 700,000 deaths globally each year. This is predicated to rise to 10M deaths a year and cost US$100Tn in world GDP by 2050 if no action is taken2. In the UK, biofilm-mediated chronic infections are estimated to cost the NHS £7.2Bn per annum3. NBIC represents a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. Established in 2017, it is an interdisciplinary centre, bringing together 4 lead and 59 associate UK universities and their infrastructure, and support from a growing industry hub of over 250 companies (SME to multinational) across multiple sectors where biofilms offer both problems and opportunities. Given their global importance, NBIC is strongly committed to establishing new international partnerships to bring together the wide and diverse range of perspectives, needs and expertise required to address biofilm-related challenges. WACCBIP is one of the World Bank's Centres of Excellence at the University of Ghana. It was founded in 2013 and is led by faculty from the Department of Biochemistry, Cell and Molecular Biology and the Noguchi Memorial Institute for Medical Research (NMIMR) The centre conducts applied research into the biology and pathogenesis of tropical diseases and aims to increase research and innovation by enhancing collaboration among biomedical scientists and industry leaders across Africa. |
| Collaborator Contribution | Full partnership. |
| Impact | None yet |
| Start Year | 2022 |
| Description | A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens (Miguel Camara) |
| Organisation | Medicines Discovery Catapult |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | This award will allow us to establish a new synergistic partnership between the UK's National Biofilm Innovation Centre (NBIC) and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) in Ghana. Biofilms are implicated in some of the most critical global challenges and have significant economic impact across multiple sectors. They are a leading cause of chronic infections and antimicrobial resistance (AMR), described in June 2021 by G7 Health Ministers as a "silent pandemic"1 and the cause of at least 700,000 deaths globally each year. This is predicated to rise to 10M deaths a year and cost US$100Tn in world GDP by 2050 if no action is taken2. In the UK, biofilm-mediated chronic infections are estimated to cost the NHS £7.2Bn per annum3. NBIC represents a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. Established in 2017, it is an interdisciplinary centre, bringing together 4 lead and 59 associate UK universities and their infrastructure, and support from a growing industry hub of over 250 companies (SME to multinational) across multiple sectors where biofilms offer both problems and opportunities. Given their global importance, NBIC is strongly committed to establishing new international partnerships to bring together the wide and diverse range of perspectives, needs and expertise required to address biofilm-related challenges. WACCBIP is one of the World Bank's Centres of Excellence at the University of Ghana. It was founded in 2013 and is led by faculty from the Department of Biochemistry, Cell and Molecular Biology and the Noguchi Memorial Institute for Medical Research (NMIMR) The centre conducts applied research into the biology and pathogenesis of tropical diseases and aims to increase research and innovation by enhancing collaboration among biomedical scientists and industry leaders across Africa. |
| Collaborator Contribution | Full partnership. |
| Impact | None yet |
| Start Year | 2022 |
| Description | A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens (Miguel Camara) |
| Organisation | National Biofilms Innovation Centre |
| Sector | Private |
| PI Contribution | This award will allow us to establish a new synergistic partnership between the UK's National Biofilm Innovation Centre (NBIC) and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) in Ghana. Biofilms are implicated in some of the most critical global challenges and have significant economic impact across multiple sectors. They are a leading cause of chronic infections and antimicrobial resistance (AMR), described in June 2021 by G7 Health Ministers as a "silent pandemic"1 and the cause of at least 700,000 deaths globally each year. This is predicated to rise to 10M deaths a year and cost US$100Tn in world GDP by 2050 if no action is taken2. In the UK, biofilm-mediated chronic infections are estimated to cost the NHS £7.2Bn per annum3. NBIC represents a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. Established in 2017, it is an interdisciplinary centre, bringing together 4 lead and 59 associate UK universities and their infrastructure, and support from a growing industry hub of over 250 companies (SME to multinational) across multiple sectors where biofilms offer both problems and opportunities. Given their global importance, NBIC is strongly committed to establishing new international partnerships to bring together the wide and diverse range of perspectives, needs and expertise required to address biofilm-related challenges. WACCBIP is one of the World Bank's Centres of Excellence at the University of Ghana. It was founded in 2013 and is led by faculty from the Department of Biochemistry, Cell and Molecular Biology and the Noguchi Memorial Institute for Medical Research (NMIMR) The centre conducts applied research into the biology and pathogenesis of tropical diseases and aims to increase research and innovation by enhancing collaboration among biomedical scientists and industry leaders across Africa. |
| Collaborator Contribution | Full partnership. |
| Impact | None yet |
| Start Year | 2022 |
| Description | A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens (Miguel Camara) |
| Organisation | NovaBiotics Ltd, UK |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | This award will allow us to establish a new synergistic partnership between the UK's National Biofilm Innovation Centre (NBIC) and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) in Ghana. Biofilms are implicated in some of the most critical global challenges and have significant economic impact across multiple sectors. They are a leading cause of chronic infections and antimicrobial resistance (AMR), described in June 2021 by G7 Health Ministers as a "silent pandemic"1 and the cause of at least 700,000 deaths globally each year. This is predicated to rise to 10M deaths a year and cost US$100Tn in world GDP by 2050 if no action is taken2. In the UK, biofilm-mediated chronic infections are estimated to cost the NHS £7.2Bn per annum3. NBIC represents a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. Established in 2017, it is an interdisciplinary centre, bringing together 4 lead and 59 associate UK universities and their infrastructure, and support from a growing industry hub of over 250 companies (SME to multinational) across multiple sectors where biofilms offer both problems and opportunities. Given their global importance, NBIC is strongly committed to establishing new international partnerships to bring together the wide and diverse range of perspectives, needs and expertise required to address biofilm-related challenges. WACCBIP is one of the World Bank's Centres of Excellence at the University of Ghana. It was founded in 2013 and is led by faculty from the Department of Biochemistry, Cell and Molecular Biology and the Noguchi Memorial Institute for Medical Research (NMIMR) The centre conducts applied research into the biology and pathogenesis of tropical diseases and aims to increase research and innovation by enhancing collaboration among biomedical scientists and industry leaders across Africa. |
| Collaborator Contribution | Full partnership. |
| Impact | None yet |
| Start Year | 2022 |
| Description | A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens (Miguel Camara) |
| Organisation | University of Ghana |
| Department | West Africa Centre for Cell Biology of Infectious Pathogens |
| Country | Ghana |
| Sector | Academic/University |
| PI Contribution | This award will allow us to establish a new synergistic partnership between the UK's National Biofilm Innovation Centre (NBIC) and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) in Ghana. Biofilms are implicated in some of the most critical global challenges and have significant economic impact across multiple sectors. They are a leading cause of chronic infections and antimicrobial resistance (AMR), described in June 2021 by G7 Health Ministers as a "silent pandemic"1 and the cause of at least 700,000 deaths globally each year. This is predicated to rise to 10M deaths a year and cost US$100Tn in world GDP by 2050 if no action is taken2. In the UK, biofilm-mediated chronic infections are estimated to cost the NHS £7.2Bn per annum3. NBIC represents a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. Established in 2017, it is an interdisciplinary centre, bringing together 4 lead and 59 associate UK universities and their infrastructure, and support from a growing industry hub of over 250 companies (SME to multinational) across multiple sectors where biofilms offer both problems and opportunities. Given their global importance, NBIC is strongly committed to establishing new international partnerships to bring together the wide and diverse range of perspectives, needs and expertise required to address biofilm-related challenges. WACCBIP is one of the World Bank's Centres of Excellence at the University of Ghana. It was founded in 2013 and is led by faculty from the Department of Biochemistry, Cell and Molecular Biology and the Noguchi Memorial Institute for Medical Research (NMIMR) The centre conducts applied research into the biology and pathogenesis of tropical diseases and aims to increase research and innovation by enhancing collaboration among biomedical scientists and industry leaders across Africa. |
| Collaborator Contribution | Full partnership. |
| Impact | None yet |
| Start Year | 2022 |
| Description | A joint workshop between the UK's National Biofilm Innovation Centre and the West African Centre for Cell Biology of Infectious Pathogens (Miguel Camara) |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This award will allow us to establish a new synergistic partnership between the UK's National Biofilm Innovation Centre (NBIC) and the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) in Ghana. Biofilms are implicated in some of the most critical global challenges and have significant economic impact across multiple sectors. They are a leading cause of chronic infections and antimicrobial resistance (AMR), described in June 2021 by G7 Health Ministers as a "silent pandemic"1 and the cause of at least 700,000 deaths globally each year. This is predicated to rise to 10M deaths a year and cost US$100Tn in world GDP by 2050 if no action is taken2. In the UK, biofilm-mediated chronic infections are estimated to cost the NHS £7.2Bn per annum3. NBIC represents a fusion of world-class research and industry to deliver breakthrough technologies in the control and exploitation of biofilms. Established in 2017, it is an interdisciplinary centre, bringing together 4 lead and 59 associate UK universities and their infrastructure, and support from a growing industry hub of over 250 companies (SME to multinational) across multiple sectors where biofilms offer both problems and opportunities. Given their global importance, NBIC is strongly committed to establishing new international partnerships to bring together the wide and diverse range of perspectives, needs and expertise required to address biofilm-related challenges. WACCBIP is one of the World Bank's Centres of Excellence at the University of Ghana. It was founded in 2013 and is led by faculty from the Department of Biochemistry, Cell and Molecular Biology and the Noguchi Memorial Institute for Medical Research (NMIMR) The centre conducts applied research into the biology and pathogenesis of tropical diseases and aims to increase research and innovation by enhancing collaboration among biomedical scientists and industry leaders across Africa. |
| Collaborator Contribution | Full partnership. |
| Impact | None yet |
| Start Year | 2022 |
| Description | Agent Energy and HVB PoC (Eileen Yu) |
| Organisation | Argent Energy |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Through this collaboration, the aim of this research is to develop an optimised MES process with enhanced selectivity for high-value long-chain carbohydrates (C4-C8) production. |
| Collaborator Contribution | Argent Energy will contribute in several ways for this project as a research partner. This includes providing: • Information on effluent waste gas enriched with CO2, and effluent organic waste streams; • Advice on research questions and directions for the project; • Staff time in project evaluation and taking part in project review meetings, • Access to site visits and relevant on-site data. |
| Impact | Secured a BBSRC High value Biorenewables PoC funding with the project Enhance selectivity for high value bioproducts from CO2 and waste organics through microbial electrosynthesis. |
| Start Year | 2021 |
| Description | Agent Energy and HVB PoC (Eileen Yu) |
| Organisation | Loughborough University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Through this collaboration, the aim of this research is to develop an optimised MES process with enhanced selectivity for high-value long-chain carbohydrates (C4-C8) production. |
| Collaborator Contribution | Argent Energy will contribute in several ways for this project as a research partner. This includes providing: • Information on effluent waste gas enriched with CO2, and effluent organic waste streams; • Advice on research questions and directions for the project; • Staff time in project evaluation and taking part in project review meetings, • Access to site visits and relevant on-site data. |
| Impact | Secured a BBSRC High value Biorenewables PoC funding with the project Enhance selectivity for high value bioproducts from CO2 and waste organics through microbial electrosynthesis. |
| Start Year | 2021 |
| Description | An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) |
| Organisation | AlgiPharma |
| Country | Norway |
| Sector | Private |
| PI Contribution | NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods. |
| Collaborator Contribution | The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada. |
| Impact | No outputs yet. |
| Start Year | 2021 |
| Description | An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods. |
| Collaborator Contribution | The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada. |
| Impact | No outputs yet. |
| Start Year | 2021 |
| Description | An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) |
| Organisation | Cystic Fibrosis Foundation |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods. |
| Collaborator Contribution | The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada. |
| Impact | No outputs yet. |
| Start Year | 2021 |
| Description | An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) |
| Organisation | Cystic Fibrosis Trust |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods. |
| Collaborator Contribution | The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada. |
| Impact | No outputs yet. |
| Start Year | 2021 |
| Description | An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) |
| Organisation | Georgia Institute of Technology |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods. |
| Collaborator Contribution | The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada. |
| Impact | No outputs yet. |
| Start Year | 2021 |
| Description | An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) |
| Organisation | Liverpool Heart and Chest Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods. |
| Collaborator Contribution | The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada. |
| Impact | No outputs yet. |
| Start Year | 2021 |
| Description | An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) |
| Organisation | Manchester University NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods. |
| Collaborator Contribution | The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada. |
| Impact | No outputs yet. |
| Start Year | 2021 |
| Description | An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) |
| Organisation | Medicines Discovery Catapult |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods. |
| Collaborator Contribution | The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada. |
| Impact | No outputs yet. |
| Start Year | 2021 |
| Description | An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods. |
| Collaborator Contribution | The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada. |
| Impact | No outputs yet. |
| Start Year | 2021 |
| Description | An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) |
| Organisation | University of Laval |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods. |
| Collaborator Contribution | The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada. |
| Impact | No outputs yet. |
| Start Year | 2021 |
| Description | An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods. |
| Collaborator Contribution | The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada. |
| Impact | No outputs yet. |
| Start Year | 2021 |
| Description | An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). (Miguel Camara) |
| Organisation | University of Warwick |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | NBIC core partners, the Universities of Liverpool and Nottingham, are leading on a Strategic Research Centre as part of a new international collaboration to accelerate the development of much needed antibiotics for cystic fibrosis (CF) lung infections. Supported by £750,000 of funding from the Cystic Fibrosis Trust and the CF Foundation in the United States, the Strategic Research Centre will develop new laboratory methods to make it quicker and easier for researchers to test new medicines for CF. New Treatments Cystic Fibrosis Most people with CF will develop lung infections throughout their lifetimes. Once the bugs that cause the infections adapt to the environment of CF lungs they can be extremely difficult to treat. In some cases, the bugs are becoming resistant to the strongest medicines that are available. Left untreated, these infections can trigger permanent lung damage, meaning people are more breathless and have less energy to do day-to-day activities. More effective treatments with fewer side effects are urgently needed. Researchers around the world are currently working on the development of new medicines to treat CF lung infections. However, there are differences and gaps in how different researchers test new CF medicines in the laboratory meaning that the results are not comparable, which slows down progress. In addition, the tests that are used were not originally designed specifically to test CF medicines. For example, the tests don't mimic the effects of the thick sticky mucus found in the lungs of people with CF. This makes it hard to assess whether a potential medicine will work. The new four-year Strategic Research Centre (SRC) led by Dr Jo Fothergill at the University of Liverpool with Professor Miguel Cámara from the University of Nottingham as the deputy lead will develop a new set of laboratory methods specifically designed for testing new medicines for CF. The SRC will combine expertise in understanding the infection-causing bugs Pseudomonas aeruginosa, NTM and Burkholderia cepacia complex, with expertise in developing new lab methods. |
| Collaborator Contribution | The SRC also involves co-investigators from Cambridge, Cardiff and Warwick; Liverpool Heart and Chest Hospital; Manchester University Hospitals NHS Trust; Georgia Institute of Technology in the USA and the Institut de biologie Intégrative et des systems in Quebec, Canada. |
| Impact | No outputs yet. |
| Start Year | 2021 |
| Description | Anti biofilm lactam technology |
| Organisation | Unilever |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | prior knowledge on biofilm and anti-biofilm protocols and related microbiology. chemical synthesis and bacterial strains. |
| Collaborator Contribution | discussion of project processes, provision of reagents, industrial placement |
| Impact | not yet |
| Start Year | 2019 |
| Description | Areas of energy and resource recovery during environmental processes such as wastewater treatment and reuse (Mohamed Mamlouk) |
| Organisation | Newcastle University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Ideas and discussion of possible joint projects. |
| Collaborator Contribution | Host visitor and materials supply. |
| Impact | Multi-disciplinary linking biology , electrochemistry and civil engineering. |
| Start Year | 2020 |
| Description | Areas of energy and resource recovery during environmental processes such as wastewater treatment and reuse (Mohamed Mamlouk) |
| Organisation | Princeton University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Ideas and discussion of possible joint projects. |
| Collaborator Contribution | Host visitor and materials supply. |
| Impact | Multi-disciplinary linking biology , electrochemistry and civil engineering. |
| Start Year | 2020 |
| Description | Assessment and optimisation of probiotic therapeutics against bacterial vaginosis biofilms (Ryan Kean) |
| Organisation | Ferring Pharmaceuticals |
| Country | Switzerland |
| Sector | Private |
| PI Contribution | The data generated from NBIC POC 04POC21-235 has been used to secure £51,977 in funding from Ferring Pharmaceuticals to Glasgow Caledonian University, to investigate probiotic therapies against the BV model which was designed in this project. It is anticipated that future work packages will be follow on from this initial 5-month project. |
| Collaborator Contribution | Contract research. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | Assessment and optimisation of probiotic therapeutics against bacterial vaginosis biofilms (Ryan Kean) |
| Organisation | Glasgow Caledonian University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The data generated from NBIC POC 04POC21-235 has been used to secure £51,977 in funding from Ferring Pharmaceuticals to Glasgow Caledonian University, to investigate probiotic therapies against the BV model which was designed in this project. It is anticipated that future work packages will be follow on from this initial 5-month project. |
| Collaborator Contribution | Contract research. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | BBSRC CTP application (Paulina Rakowska) |
| Organisation | 5D Health Protection Group Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000. |
| Collaborator Contribution | NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB. |
| Impact | Consortium awarded funds for 15 PhDs. Award around £1.5 million. |
| Start Year | 2020 |
| Description | BBSRC CTP application (Paulina Rakowska) |
| Organisation | BP (British Petroleum) |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000. |
| Collaborator Contribution | NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB. |
| Impact | Consortium awarded funds for 15 PhDs. Award around £1.5 million. |
| Start Year | 2020 |
| Description | BBSRC CTP application (Paulina Rakowska) |
| Organisation | Chilled Food Association |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000. |
| Collaborator Contribution | NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB. |
| Impact | Consortium awarded funds for 15 PhDs. Award around £1.5 million. |
| Start Year | 2020 |
| Description | BBSRC CTP application (Paulina Rakowska) |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000. |
| Collaborator Contribution | NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB. |
| Impact | Consortium awarded funds for 15 PhDs. Award around £1.5 million. |
| Start Year | 2020 |
| Description | BBSRC CTP application (Paulina Rakowska) |
| Organisation | Industrial Biotechnology Innovation Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000. |
| Collaborator Contribution | NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB. |
| Impact | Consortium awarded funds for 15 PhDs. Award around £1.5 million. |
| Start Year | 2020 |
| Description | BBSRC CTP application (Paulina Rakowska) |
| Organisation | Kohler Co |
| Country | United States |
| Sector | Private |
| PI Contribution | Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000. |
| Collaborator Contribution | NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB. |
| Impact | Consortium awarded funds for 15 PhDs. Award around £1.5 million. |
| Start Year | 2020 |
| Description | BBSRC CTP application (Paulina Rakowska) |
| Organisation | Smith and Nephew |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000. |
| Collaborator Contribution | NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB. |
| Impact | Consortium awarded funds for 15 PhDs. Award around £1.5 million. |
| Start Year | 2020 |
| Description | BBSRC CTP application (Paulina Rakowska) |
| Organisation | Unilever |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Developed application to BBSRC Collaborative Training Partnership scheme, where the lead applicant and industry partner is Smith & Nephew PLC, acting as a member of and on behalf of the NBICs Industry Advisory Board, supported by NBIC operational Team, who will supply the infrastructure to manage this programme and will coordinate the delivery of the cohort training. Grant value: over £1,500,000. |
| Collaborator Contribution | NBICs Industry Advisory Board (Smith&Nephew, Unilever, GlaxoSmithKline, BP, Chilled Food Association, 5D Health Protection Group Ltd, Industrial Technology Innovation Centre (IBioIC) and Kohler Co), are the full partner on the proposal. The NBIC AIB co-developed the proposal by providing advise and direction to the shape of the CTP. Smith & Nephew is the main applicant, acting on behalf of the NBIC AIB. |
| Impact | Consortium awarded funds for 15 PhDs. Award around £1.5 million. |
| Start Year | 2020 |
| Description | BBSRC Global Partnering Award - collaborative proposal between NBIC and India Biofilm Society (Paulina Rakowska) |
| Organisation | Regional Centre for Biotechnology |
| Country | India |
| Sector | Public |
| PI Contribution | Developed and submitted collaborative proposal to the BBSRC International Partnering Awards: India Partnering Award: Building globally leading partnership between India and UK's biofilm innovation centres. Collaboration between NBIC and India Biofilms Society. funding sought: £30000. |
| Collaborator Contribution | Co-developed the proposal with intended in-kind contribution of £30000. |
| Impact | Submitted proposal - unsuccessful. |
| Start Year | 2020 |
| Description | BBSRC Global Partnering Award - collaborative proposal between NBIC and India Biofilm Society (Paulina Rakowska) |
| Organisation | SASTRA University |
| Country | India |
| Sector | Academic/University |
| PI Contribution | Developed and submitted collaborative proposal to the BBSRC International Partnering Awards: India Partnering Award: Building globally leading partnership between India and UK's biofilm innovation centres. Collaboration between NBIC and India Biofilms Society. funding sought: £30000. |
| Collaborator Contribution | Co-developed the proposal with intended in-kind contribution of £30000. |
| Impact | Submitted proposal - unsuccessful. |
| Start Year | 2020 |
| Description | BBSRC Global Partnering Award - collaborative proposal between NBIC and India Biofilm Society (Paulina Rakowska) |
| Organisation | Savitribai Phule Pune University |
| Country | India |
| Sector | Academic/University |
| PI Contribution | Developed and submitted collaborative proposal to the BBSRC International Partnering Awards: India Partnering Award: Building globally leading partnership between India and UK's biofilm innovation centres. Collaboration between NBIC and India Biofilms Society. funding sought: £30000. |
| Collaborator Contribution | Co-developed the proposal with intended in-kind contribution of £30000. |
| Impact | Submitted proposal - unsuccessful. |
| Start Year | 2020 |
| Description | BBSRC Global Partnering Award - collaborative proposal between NBIC and India Biofilm Society (Paulina Rakowska) |
| Organisation | Tripura University |
| Country | India |
| Sector | Academic/University |
| PI Contribution | Developed and submitted collaborative proposal to the BBSRC International Partnering Awards: India Partnering Award: Building globally leading partnership between India and UK's biofilm innovation centres. Collaboration between NBIC and India Biofilms Society. funding sought: £30000. |
| Collaborator Contribution | Co-developed the proposal with intended in-kind contribution of £30000. |
| Impact | Submitted proposal - unsuccessful. |
| Start Year | 2020 |
| Description | BBSRC and MRC Ageing Across the Lifecourse Networks (Peter Smith) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | This is a BBSRC funded project reference BB/W018284/1. MyAge will break down the silos associated with reductionist research and bring together non-overlapping expertise of researchers, industrialists and stakeholders from muscle research, me-tabolism, regenerative medicine, genomics, epigenetics, maths, data and social sciences, health inequity, biotech and pharma to understand the mechanistic pathways of muscle development, differentiation and decline. Although considerable research has focused on the better understand-ing of the determinants of muscle ageing, the complexity of the ageing process itself requires an innovative research approach that shifts away from studying single systems in isolation towards an integrative and holistic understanding of muscle ageing where multidimensional molecular, physio-logical, organism and population level research is combined. This approach aligns strongly with rec-ommendations in The Physiological Society's report, "Growing older, better". MyAge will develop a ROADMAP that seeks to inform policy and UKRI funding calls. |
| Collaborator Contribution | In partnership with stakeholders and industry partners we will explore interventions as well as therapeutic and lifestyle modifications that impact the progression of muscle differentiation and decline from a cellular and functional perspective. MyAge will gather researchers with expertise in regenerative biology, epigenetics, single cell analysis, nanotechnology, electrophysiology, molecular phenotyping, mitochondrial function, inflammation, endocrinology, organoid culture, performance, human ageing cohorts, and social impact. Using various model systems from nematodes to humans, the network will uncover how the molecular and metabolic landscape of myofibers, SC and non-SC progenitors and muscle tissue architecture change with ageing and through exposures to different environmental stimuli. We will integrate this knowledge with epidemiological, nutritional, societal and health inequity and inequality data. Using fMRI to image muscle during exercise will allow us to investigate the physiological basis of anabolic resistance With the latest advances in topological analysis, we will integrate complex, high dimensional data sets to unravel the fundamental mecha-nisms of muscle ageing and to define how the environmental factors though the life course affect muscle cell physiology, ageing and life course trajectory. MyAge is a new network of individual members, organisations and partners who have not previously worked together in this manner. It represents a new synthesis of disciplines. Within our membership there are pre-existing networks dealing with particular specialties, for exam-ple CMAR, (29 members from Birmingham and 22 from Nottingham). Additional networks of inves-tigators are CIMA, the Southampton Lifecourse Epidemiology Centre, the BRC Nutrition and Lifecourse theme and the IfLS. The latter has a membership of 350 investigators crossing the STEM subjects, Medicine, Health and Sociology. Bringing these groups together, alongside our individual members and partners, societies and enterprise, has never been done before. This novelty of inter-action will expedite the generation of new insights, pathways and strategies to address the chal-lenges of ageing. Although MyAge will focus on muscle ageing, our members and approach will add value to, and learn from, the proposed macro-coordination of the Ageing networks. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | BBSRC and MRC Ageing Across the Lifecourse Networks (Peter Smith) |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This is a BBSRC funded project reference BB/W018284/1. MyAge will break down the silos associated with reductionist research and bring together non-overlapping expertise of researchers, industrialists and stakeholders from muscle research, me-tabolism, regenerative medicine, genomics, epigenetics, maths, data and social sciences, health inequity, biotech and pharma to understand the mechanistic pathways of muscle development, differentiation and decline. Although considerable research has focused on the better understand-ing of the determinants of muscle ageing, the complexity of the ageing process itself requires an innovative research approach that shifts away from studying single systems in isolation towards an integrative and holistic understanding of muscle ageing where multidimensional molecular, physio-logical, organism and population level research is combined. This approach aligns strongly with rec-ommendations in The Physiological Society's report, "Growing older, better". MyAge will develop a ROADMAP that seeks to inform policy and UKRI funding calls. |
| Collaborator Contribution | In partnership with stakeholders and industry partners we will explore interventions as well as therapeutic and lifestyle modifications that impact the progression of muscle differentiation and decline from a cellular and functional perspective. MyAge will gather researchers with expertise in regenerative biology, epigenetics, single cell analysis, nanotechnology, electrophysiology, molecular phenotyping, mitochondrial function, inflammation, endocrinology, organoid culture, performance, human ageing cohorts, and social impact. Using various model systems from nematodes to humans, the network will uncover how the molecular and metabolic landscape of myofibers, SC and non-SC progenitors and muscle tissue architecture change with ageing and through exposures to different environmental stimuli. We will integrate this knowledge with epidemiological, nutritional, societal and health inequity and inequality data. Using fMRI to image muscle during exercise will allow us to investigate the physiological basis of anabolic resistance With the latest advances in topological analysis, we will integrate complex, high dimensional data sets to unravel the fundamental mecha-nisms of muscle ageing and to define how the environmental factors though the life course affect muscle cell physiology, ageing and life course trajectory. MyAge is a new network of individual members, organisations and partners who have not previously worked together in this manner. It represents a new synthesis of disciplines. Within our membership there are pre-existing networks dealing with particular specialties, for exam-ple CMAR, (29 members from Birmingham and 22 from Nottingham). Additional networks of inves-tigators are CIMA, the Southampton Lifecourse Epidemiology Centre, the BRC Nutrition and Lifecourse theme and the IfLS. The latter has a membership of 350 investigators crossing the STEM subjects, Medicine, Health and Sociology. Bringing these groups together, alongside our individual members and partners, societies and enterprise, has never been done before. This novelty of inter-action will expedite the generation of new insights, pathways and strategies to address the chal-lenges of ageing. Although MyAge will focus on muscle ageing, our members and approach will add value to, and learn from, the proposed macro-coordination of the Ageing networks. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | BBSRC and MRC Ageing Across the Lifecourse Networks (Peter Smith) |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This is a BBSRC funded project reference BB/W018284/1. MyAge will break down the silos associated with reductionist research and bring together non-overlapping expertise of researchers, industrialists and stakeholders from muscle research, me-tabolism, regenerative medicine, genomics, epigenetics, maths, data and social sciences, health inequity, biotech and pharma to understand the mechanistic pathways of muscle development, differentiation and decline. Although considerable research has focused on the better understand-ing of the determinants of muscle ageing, the complexity of the ageing process itself requires an innovative research approach that shifts away from studying single systems in isolation towards an integrative and holistic understanding of muscle ageing where multidimensional molecular, physio-logical, organism and population level research is combined. This approach aligns strongly with rec-ommendations in The Physiological Society's report, "Growing older, better". MyAge will develop a ROADMAP that seeks to inform policy and UKRI funding calls. |
| Collaborator Contribution | In partnership with stakeholders and industry partners we will explore interventions as well as therapeutic and lifestyle modifications that impact the progression of muscle differentiation and decline from a cellular and functional perspective. MyAge will gather researchers with expertise in regenerative biology, epigenetics, single cell analysis, nanotechnology, electrophysiology, molecular phenotyping, mitochondrial function, inflammation, endocrinology, organoid culture, performance, human ageing cohorts, and social impact. Using various model systems from nematodes to humans, the network will uncover how the molecular and metabolic landscape of myofibers, SC and non-SC progenitors and muscle tissue architecture change with ageing and through exposures to different environmental stimuli. We will integrate this knowledge with epidemiological, nutritional, societal and health inequity and inequality data. Using fMRI to image muscle during exercise will allow us to investigate the physiological basis of anabolic resistance With the latest advances in topological analysis, we will integrate complex, high dimensional data sets to unravel the fundamental mecha-nisms of muscle ageing and to define how the environmental factors though the life course affect muscle cell physiology, ageing and life course trajectory. MyAge is a new network of individual members, organisations and partners who have not previously worked together in this manner. It represents a new synthesis of disciplines. Within our membership there are pre-existing networks dealing with particular specialties, for exam-ple CMAR, (29 members from Birmingham and 22 from Nottingham). Additional networks of inves-tigators are CIMA, the Southampton Lifecourse Epidemiology Centre, the BRC Nutrition and Lifecourse theme and the IfLS. The latter has a membership of 350 investigators crossing the STEM subjects, Medicine, Health and Sociology. Bringing these groups together, alongside our individual members and partners, societies and enterprise, has never been done before. This novelty of inter-action will expedite the generation of new insights, pathways and strategies to address the chal-lenges of ageing. Although MyAge will focus on muscle ageing, our members and approach will add value to, and learn from, the proposed macro-coordination of the Ageing networks. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | BBSRC and MRC Ageing Across the Lifecourse Networks (Peter Smith) |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This is a BBSRC funded project reference BB/W018284/1. MyAge will break down the silos associated with reductionist research and bring together non-overlapping expertise of researchers, industrialists and stakeholders from muscle research, me-tabolism, regenerative medicine, genomics, epigenetics, maths, data and social sciences, health inequity, biotech and pharma to understand the mechanistic pathways of muscle development, differentiation and decline. Although considerable research has focused on the better understand-ing of the determinants of muscle ageing, the complexity of the ageing process itself requires an innovative research approach that shifts away from studying single systems in isolation towards an integrative and holistic understanding of muscle ageing where multidimensional molecular, physio-logical, organism and population level research is combined. This approach aligns strongly with rec-ommendations in The Physiological Society's report, "Growing older, better". MyAge will develop a ROADMAP that seeks to inform policy and UKRI funding calls. |
| Collaborator Contribution | In partnership with stakeholders and industry partners we will explore interventions as well as therapeutic and lifestyle modifications that impact the progression of muscle differentiation and decline from a cellular and functional perspective. MyAge will gather researchers with expertise in regenerative biology, epigenetics, single cell analysis, nanotechnology, electrophysiology, molecular phenotyping, mitochondrial function, inflammation, endocrinology, organoid culture, performance, human ageing cohorts, and social impact. Using various model systems from nematodes to humans, the network will uncover how the molecular and metabolic landscape of myofibers, SC and non-SC progenitors and muscle tissue architecture change with ageing and through exposures to different environmental stimuli. We will integrate this knowledge with epidemiological, nutritional, societal and health inequity and inequality data. Using fMRI to image muscle during exercise will allow us to investigate the physiological basis of anabolic resistance With the latest advances in topological analysis, we will integrate complex, high dimensional data sets to unravel the fundamental mecha-nisms of muscle ageing and to define how the environmental factors though the life course affect muscle cell physiology, ageing and life course trajectory. MyAge is a new network of individual members, organisations and partners who have not previously worked together in this manner. It represents a new synthesis of disciplines. Within our membership there are pre-existing networks dealing with particular specialties, for exam-ple CMAR, (29 members from Birmingham and 22 from Nottingham). Additional networks of inves-tigators are CIMA, the Southampton Lifecourse Epidemiology Centre, the BRC Nutrition and Lifecourse theme and the IfLS. The latter has a membership of 350 investigators crossing the STEM subjects, Medicine, Health and Sociology. Bringing these groups together, alongside our individual members and partners, societies and enterprise, has never been done before. This novelty of inter-action will expedite the generation of new insights, pathways and strategies to address the chal-lenges of ageing. Although MyAge will focus on muscle ageing, our members and approach will add value to, and learn from, the proposed macro-coordination of the Ageing networks. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | BBSRC and MRC Ageing Across the Lifecourse Networks (Peter Smith) |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This is a BBSRC funded project reference BB/W018284/1. MyAge will break down the silos associated with reductionist research and bring together non-overlapping expertise of researchers, industrialists and stakeholders from muscle research, me-tabolism, regenerative medicine, genomics, epigenetics, maths, data and social sciences, health inequity, biotech and pharma to understand the mechanistic pathways of muscle development, differentiation and decline. Although considerable research has focused on the better understand-ing of the determinants of muscle ageing, the complexity of the ageing process itself requires an innovative research approach that shifts away from studying single systems in isolation towards an integrative and holistic understanding of muscle ageing where multidimensional molecular, physio-logical, organism and population level research is combined. This approach aligns strongly with rec-ommendations in The Physiological Society's report, "Growing older, better". MyAge will develop a ROADMAP that seeks to inform policy and UKRI funding calls. |
| Collaborator Contribution | In partnership with stakeholders and industry partners we will explore interventions as well as therapeutic and lifestyle modifications that impact the progression of muscle differentiation and decline from a cellular and functional perspective. MyAge will gather researchers with expertise in regenerative biology, epigenetics, single cell analysis, nanotechnology, electrophysiology, molecular phenotyping, mitochondrial function, inflammation, endocrinology, organoid culture, performance, human ageing cohorts, and social impact. Using various model systems from nematodes to humans, the network will uncover how the molecular and metabolic landscape of myofibers, SC and non-SC progenitors and muscle tissue architecture change with ageing and through exposures to different environmental stimuli. We will integrate this knowledge with epidemiological, nutritional, societal and health inequity and inequality data. Using fMRI to image muscle during exercise will allow us to investigate the physiological basis of anabolic resistance With the latest advances in topological analysis, we will integrate complex, high dimensional data sets to unravel the fundamental mecha-nisms of muscle ageing and to define how the environmental factors though the life course affect muscle cell physiology, ageing and life course trajectory. MyAge is a new network of individual members, organisations and partners who have not previously worked together in this manner. It represents a new synthesis of disciplines. Within our membership there are pre-existing networks dealing with particular specialties, for exam-ple CMAR, (29 members from Birmingham and 22 from Nottingham). Additional networks of inves-tigators are CIMA, the Southampton Lifecourse Epidemiology Centre, the BRC Nutrition and Lifecourse theme and the IfLS. The latter has a membership of 350 investigators crossing the STEM subjects, Medicine, Health and Sociology. Bringing these groups together, alongside our individual members and partners, societies and enterprise, has never been done before. This novelty of inter-action will expedite the generation of new insights, pathways and strategies to address the chal-lenges of ageing. Although MyAge will focus on muscle ageing, our members and approach will add value to, and learn from, the proposed macro-coordination of the Ageing networks. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | Biofilms ICURe Sprint programme |
| Organisation | National Biofilms Innovation Centre |
| Sector | Private |
| PI Contribution | Funding to support 6 early career researchers through the ICURe program to develop their commercially promising research. |
| Collaborator Contribution | Training to enable the teams to 'get out of the lab' and validate their commercially promising research over eight weeks. |
| Impact | So far, two research teams that took part in the Biofilms ICURe Sprint have been awarded spin-out funding to transform their innovations into market-ready businesses. |
| Start Year | 2022 |
| Description | Biofilms ICURe Sprint programme |
| Organisation | SETsquared Partnership |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Funding to support 6 early career researchers through the ICURe program to develop their commercially promising research. |
| Collaborator Contribution | Training to enable the teams to 'get out of the lab' and validate their commercially promising research over eight weeks. |
| Impact | So far, two research teams that took part in the Biofilms ICURe Sprint have been awarded spin-out funding to transform their innovations into market-ready businesses. |
| Start Year | 2022 |
| Description | Britest collaboration on cleaning (William Zimmerman) |
| Organisation | Britest |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Britest is a non-profit service company set up by it industrial consortium membership for the intensification of batch processing, drawing from biopharma, fine chemicals, agrichemicals and other process industries for its base. Britest has an ongoing initiative for better process cleaning, decontamination, disinfection and related technologies. Professor Joan Cordiner who joined the University of Sheffield and I presented our portfolio of cleaning related research activities to the Britest Symposium 21,22 January 2021 this year. The acting MD of Britest is liaising with the membership on our behalf to collaborate on EPSRC and InnovateUK grant proposals. Professor Cordiner's industrial background includes building expert systems for scheduling industrial plant / unit operation cleaning regimes. |
| Collaborator Contribution | We are currently consortium building. We have a two page executive summary of the advances and research goals for the joint industry-academe programme, including the possibility of testing on the University of Sheffield unique £2m pilot plant tabletting facility for pharmaceutical engineering. In exchanges with industrial contacts, this is a facility that they would like to access for improving their cleaning regimes offline, i.e. not on their own production facility with valuable pharmaceuticals at full scale. |
| Impact | Dissemination at the moment. Next major activity will be publication of the results of the NBIC funded feasibility study on biofilm removal. The final report is an excellent starting point. |
| Start Year | 2020 |
| Description | Britest collaboration on cleaning (William Zimmerman) |
| Organisation | University of Sheffield |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Britest is a non-profit service company set up by it industrial consortium membership for the intensification of batch processing, drawing from biopharma, fine chemicals, agrichemicals and other process industries for its base. Britest has an ongoing initiative for better process cleaning, decontamination, disinfection and related technologies. Professor Joan Cordiner who joined the University of Sheffield and I presented our portfolio of cleaning related research activities to the Britest Symposium 21,22 January 2021 this year. The acting MD of Britest is liaising with the membership on our behalf to collaborate on EPSRC and InnovateUK grant proposals. Professor Cordiner's industrial background includes building expert systems for scheduling industrial plant / unit operation cleaning regimes. |
| Collaborator Contribution | We are currently consortium building. We have a two page executive summary of the advances and research goals for the joint industry-academe programme, including the possibility of testing on the University of Sheffield unique £2m pilot plant tabletting facility for pharmaceutical engineering. In exchanges with industrial contacts, this is a facility that they would like to access for improving their cleaning regimes offline, i.e. not on their own production facility with valuable pharmaceuticals at full scale. |
| Impact | Dissemination at the moment. Next major activity will be publication of the results of the NBIC funded feasibility study on biofilm removal. The final report is an excellent starting point. |
| Start Year | 2020 |
| Description | Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina. |
| Collaborator Contribution | Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals. |
| Impact | None yet. |
| Start Year | 2021 |
| Description | Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) |
| Organisation | National Biofilms Innovation Centre |
| Sector | Private |
| PI Contribution | Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina. |
| Collaborator Contribution | Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals. |
| Impact | None yet. |
| Start Year | 2021 |
| Description | Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) |
| Organisation | National Institute of Agricultural Technology |
| Country | Argentina |
| Sector | Public |
| PI Contribution | Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina. |
| Collaborator Contribution | Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals. |
| Impact | None yet. |
| Start Year | 2021 |
| Description | Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) |
| Organisation | National Scientific and Technical Research Council (Argentina) |
| Country | Argentina |
| Sector | Public |
| PI Contribution | Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina. |
| Collaborator Contribution | Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals. |
| Impact | None yet. |
| Start Year | 2021 |
| Description | Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) |
| Organisation | National University of Rosario |
| Country | Argentina |
| Sector | Academic/University |
| PI Contribution | Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina. |
| Collaborator Contribution | Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals. |
| Impact | None yet. |
| Start Year | 2021 |
| Description | Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) |
| Organisation | National University of Río Cuarto |
| Country | Argentina |
| Sector | Academic/University |
| PI Contribution | Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina. |
| Collaborator Contribution | Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals. |
| Impact | None yet. |
| Start Year | 2021 |
| Description | Building a globally leading partnership between the UK National Biofilms Innovation Centre and Argentina (Miguel Camara) |
| Organisation | University of La Plata |
| Country | Argentina |
| Sector | Academic/University |
| PI Contribution | Microbes are key in sustainable crop production but there are many unknowns on how populations of bacteria and fungi communities known as biofilms influence plant behaviour and impact on plant nutrition and protection, soil quality,bioremediation and climate change. This award brings together researchers/industry from the UK's National Biofilms Innovation Centre and Argentina to address this knowledge gap and improve agricultural productivity in both countries reducing the use of chemical treatments and their environmental impact. The objectives are to:-Bring together complementary academic/industrial expertise from these countries on the exploitation of biofilms in agriculture-Identify the key knowledge gaps and research challenges in this area of agricultural impact.-Develop a white paper that establishes priority research areas to address these gaps.-Create future research collaborations for the use of biofilms in crop production between the Uk and Argentina. |
| Collaborator Contribution | Specific activities that will arise as outcomes from this collaborative programme include: •A joint UK-Argentine forumto share knowledge and facilitate future collaborations•Production and publication ofa 'white paper'on the current state of art, practices, challenges and research priority areasin the utilisation of plant -microbe interactionsin crop production in the UK, Argentina and globally.•Research internships for UK early career researchersto visitArgentinian institutions. These will be achieved through targeted calls subsidised by this award and based on the research priorities outlined in the white paper. The UKand Argentinianinstitutions will seekfurther funding to host Argentinian early career researchers. •Ajoint NBIC-SAMIGE/SAIB webinar seriesopenedto the international research community with talks from academic and industrial representatives to increase awareness of the research and innovation activities carried out within this collaborative partnership.•The establishment of a long-term strategic research programmebetween NBIC and the Argentinian partners enabling theco-development of jointfunding proposals. |
| Impact | None yet. |
| Start Year | 2021 |
| Description | CF AMR Syndicate |
| Organisation | Cystic Fibrosis Trust |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Prof. Miguel Camara is a member of the Cystic Fibrosis AMR Syndicate Steering Committee as NBIC representative. His role has been to represent the areas of unmet needs in biofilm research and innovation in the area of antimicrobials in cystic fibrosis contributing to the agenda of this committee. The committee meets an average of 3 times a year. |
| Collaborator Contribution | Through this CF AMR Syndicate we have designed a proposal for an in vitro drug discovery pipeline to tackle biofilms in CF. This has enable us to put together a unique consortium of researchers which has been funded to carry out this work. |
| Impact | Successful grant proposal for further collaborative work, Establishment of a UK Cystic Fibrosis Infection biorepository, Establishment of a therapeutic and a diagnostic TPP |
| Start Year | 2018 |
| Description | CF AMR Syndicate |
| Organisation | Medicines Discovery Catapult |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Prof. Miguel Camara is a member of the Cystic Fibrosis AMR Syndicate Steering Committee as NBIC representative. His role has been to represent the areas of unmet needs in biofilm research and innovation in the area of antimicrobials in cystic fibrosis contributing to the agenda of this committee. The committee meets an average of 3 times a year. |
| Collaborator Contribution | Through this CF AMR Syndicate we have designed a proposal for an in vitro drug discovery pipeline to tackle biofilms in CF. This has enable us to put together a unique consortium of researchers which has been funded to carry out this work. |
| Impact | Successful grant proposal for further collaborative work, Establishment of a UK Cystic Fibrosis Infection biorepository, Establishment of a therapeutic and a diagnostic TPP |
| Start Year | 2018 |
| Description | CF AMR Syndicate |
| Organisation | National Biofilms Innovation Centre |
| Sector | Private |
| PI Contribution | Prof. Miguel Camara is a member of the Cystic Fibrosis AMR Syndicate Steering Committee as NBIC representative. His role has been to represent the areas of unmet needs in biofilm research and innovation in the area of antimicrobials in cystic fibrosis contributing to the agenda of this committee. The committee meets an average of 3 times a year. |
| Collaborator Contribution | Through this CF AMR Syndicate we have designed a proposal for an in vitro drug discovery pipeline to tackle biofilms in CF. This has enable us to put together a unique consortium of researchers which has been funded to carry out this work. |
| Impact | Successful grant proposal for further collaborative work, Establishment of a UK Cystic Fibrosis Infection biorepository, Establishment of a therapeutic and a diagnostic TPP |
| Start Year | 2018 |
| Description | COST action |
| Organisation | BAM Federal Institute for Materials Research and Testing |
| Country | Germany |
| Sector | Public |
| PI Contribution | Cost-Action Euro-MIC has been accepted. We seems to have scored full marks in all categories. There were a total of 90 co-applicants worldwide and from all disciplines. This is the product of an interdisciplinary collaboration. |
| Collaborator Contribution | Committed to join the European MIC Network-New paths for science, sustainability and standards, when proposal will be successful. Proposal Reference OC-2020-1-24906. |
| Impact | No outcomes yet. |
| Start Year | 2021 |
| Description | CTP 2022_010 (Paired Studentship) PhD Identifying novel bacteriophage endolysins to rarget S. aureus in chronic wound biofilms |
| Organisation | Cica Biomedical Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2023 |
| Description | CTP 2022_010 (Paired Studentship) PhD Identifying novel bacteriophage endolysins to rarget S. aureus in chronic wound biofilms |
| Organisation | National Biofilms Innovation Centre |
| Sector | Private |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2023 |
| Description | CTP 2022_010 (Paired Studentship) PhD Identifying novel bacteriophage endolysins to rarget S. aureus in chronic wound biofilms |
| Organisation | University of Hull |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2023 |
| Description | CTP 2022_010 PhD Novel Endolysin to Selectively Manage Antimicrobial Resistant S. aureus in Wound Biofilms |
| Organisation | Cica Biomedical Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP 2022_010 PhD Novel Endolysin to Selectively Manage Antimicrobial Resistant S. aureus in Wound Biofilms |
| Organisation | Micreos |
| Country | Netherlands |
| Sector | Private |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP 2022_010 PhD Novel Endolysin to Selectively Manage Antimicrobial Resistant S. aureus in Wound Biofilms |
| Organisation | National Biofilms Innovation Centre |
| Sector | Private |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP 2022_010 PhD Novel Endolysin to Selectively Manage Antimicrobial Resistant S. aureus in Wound Biofilms |
| Organisation | University of Hull |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_009 (Paired Studentship) PhD Engineering biocontrol biofilms for improved protection against fungal pathogens on strawberry |
| Organisation | National Biofilms Innovation Centre |
| Sector | Private |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_009 (Paired Studentship) PhD Engineering biocontrol biofilms for improved protection against fungal pathogens on strawberry |
| Organisation | Syngenta International AG |
| Department | Syngenta Crop Protection |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_009 (Paired Studentship) PhD Engineering biocontrol biofilms for improved protection against fungal pathogens on strawberry |
| Organisation | University of Kent |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_009 PhD High resolution determination of multi-species biofilm development on tracheostomy tubing |
| Organisation | Intelligent Imaging Innovations Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_009 PhD High resolution determination of multi-species biofilm development on tracheostomy tubing |
| Organisation | National Biofilms Innovation Centre |
| Sector | Private |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_009 PhD High resolution determination of multi-species biofilm development on tracheostomy tubing |
| Organisation | University of Kent |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_017 (Paired Studentship) PhD Mapping microbial interactions on highly defined biomimetic surfaces |
| Organisation | National Biofilms Innovation Centre |
| Sector | Private |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_017 (Paired Studentship) PhD Mapping microbial interactions on highly defined biomimetic surfaces |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_021 (Paired Studentship) PhD Real-time integrated diagnosis and antimicrobial resistance profiling of infection by Raman spec-troscopy and machine learning |
| Organisation | National Biofilms Innovation Centre |
| Sector | Private |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_021 (Paired Studentship) PhD Real-time integrated diagnosis and antimicrobial resistance profiling of infection by Raman spec-troscopy and machine learning |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_021 PhD Novel multi-excitation Raman (ME-Ramen) technologies for clinical identification of respiratory biofilms in ventillator associated pnumonia (VAP) |
| Organisation | National Biofilms Innovation Centre |
| Sector | Private |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_021 PhD Novel multi-excitation Raman (ME-Ramen) technologies for clinical identification of respiratory biofilms in ventillator associated pnumonia (VAP) |
| Organisation | University Hospital Southampton NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | CTP_2022_021 PhD Novel multi-excitation Raman (ME-Ramen) technologies for clinical identification of respiratory biofilms in ventillator associated pnumonia (VAP) |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Funding, supervision and training for this PhD. |
| Collaborator Contribution | Funding, supervision and training for this PhD. |
| Impact | None yet. |
| Start Year | 2022 |
| Description | Clinical collaboration with Salford Royal NHS Foundation Trust (Mohamed El Mohtadi) |
| Organisation | Manchester Metropolitan University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Securing the FTMA has allowed me to strengthen my collaboration with 5D Health Protection Group Ltd and Manchester Metropolitan University which resulted in me obtaining a Visiting Lecturer position at MMU. The in vitro work carried out during the fellowship has attracted clinical collaborations as we are now replicating the experiments using clinical samples obtained from Salford Royal NHS Foundation Trust operated Salford Royal Hospital. |
| Collaborator Contribution | The role of collaborators (i.e. Dr Ashworth) involves the conceptualisation of project ideas and supervision of students. This will ultimately lead to increased research outcomes and the publication of several original research articles in the near future. |
| Impact | Submission of a grant bid to the Academy of Medical Sciences. The application is currently under review. |
| Start Year | 2020 |
| Description | Clinical collaboration with Salford Royal NHS Foundation Trust (Mohamed El Mohtadi) |
| Organisation | Salford Royal NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Securing the FTMA has allowed me to strengthen my collaboration with 5D Health Protection Group Ltd and Manchester Metropolitan University which resulted in me obtaining a Visiting Lecturer position at MMU. The in vitro work carried out during the fellowship has attracted clinical collaborations as we are now replicating the experiments using clinical samples obtained from Salford Royal NHS Foundation Trust operated Salford Royal Hospital. |
| Collaborator Contribution | The role of collaborators (i.e. Dr Ashworth) involves the conceptualisation of project ideas and supervision of students. This will ultimately lead to increased research outcomes and the publication of several original research articles in the near future. |
| Impact | Submission of a grant bid to the Academy of Medical Sciences. The application is currently under review. |
| Start Year | 2020 |
| Description | Collaboration on Bioinformatics with the University of Glasgow (Isabel Doutelero) |
| Organisation | Commonwealth Scientific and Industrial Research Organisation |
| Country | Australia |
| Sector | Public |
| PI Contribution | The experiments run to study climate change at the U. of Sheffield will be used to develop new bioinformatics tools by Dr Umer Ijaz (Reader in bioinformtics) at the U. of Glasgow. for drinking water systems. |
| Collaborator Contribution | Dr Ijaz will studied the use of different bioinformatics tools to study the microbial ecology of drinking water distribution systems using DNA sequencing data from Sheffield experiments. |
| Impact | Two PhD studentships have been advertised at the University of Glasgow. |
| Start Year | 2019 |
| Description | Collaboration on Bioinformatics with the University of Glasgow (Isabel Doutelero) |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The experiments run to study climate change at the U. of Sheffield will be used to develop new bioinformatics tools by Dr Umer Ijaz (Reader in bioinformtics) at the U. of Glasgow. for drinking water systems. |
| Collaborator Contribution | Dr Ijaz will studied the use of different bioinformatics tools to study the microbial ecology of drinking water distribution systems using DNA sequencing data from Sheffield experiments. |
| Impact | Two PhD studentships have been advertised at the University of Glasgow. |
| Start Year | 2019 |
| Description | Collaboration on Bioinformatics with the University of Glasgow (Isabel Doutelero) |
| Organisation | University of Sheffield |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The experiments run to study climate change at the U. of Sheffield will be used to develop new bioinformatics tools by Dr Umer Ijaz (Reader in bioinformtics) at the U. of Glasgow. for drinking water systems. |
| Collaborator Contribution | Dr Ijaz will studied the use of different bioinformatics tools to study the microbial ecology of drinking water distribution systems using DNA sequencing data from Sheffield experiments. |
| Impact | Two PhD studentships have been advertised at the University of Glasgow. |
| Start Year | 2019 |
| Description | Collaboration with Cortexyme |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Carry out contract research into the role of periodontitis in AD |
| Collaborator Contribution | Provide funding for contract research |
| Impact | No outputs yet. |
| Start Year | 2020 |
| Description | Collaboration with TopMD |
| Organisation | University of Southampton |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration Eureka Healthy Ageing Innovate UK and joint PhD studentship |
| Collaborator Contribution | Provide research data sets and research reagents |
| Impact | ARUK pump prime award (£5000) |
| Start Year | 2021 |
| Description | Collaboration with Unilever for antibacterial surface (Xinyi Zhu) |
| Organisation | Unilever |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | This project is confidentially, the details cannot be shared. Material surface characterisation has been done, and the application part is now in process. |
| Collaborator Contribution | Input into the project. |
| Impact | Details cannot be provided. |
| Start Year | 2021 |
| Description | Collaboration with Universidad Politecnica de Valencia, Spain. (Isabel Doutelero) |
| Organisation | Polytechnic University of Valencia |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Collaboration between Isabel Douterelo with Prof Joaquin Izquierdo and Dr Silvia Carpitella, on decision making tools regarding the management of drinking water systems. |
| Collaborator Contribution | Application of decision making tools to microbiological data from drinking water systems. |
| Impact | One publication submitted: https://doi.org/10.3390/w12051247 |
| Start Year | 2019 |
| Description | Collaboration with Universidad Politecnica de Valencia, Spain. (Isabel Doutelero) |
| Organisation | University of Sheffield |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration between Isabel Douterelo with Prof Joaquin Izquierdo and Dr Silvia Carpitella, on decision making tools regarding the management of drinking water systems. |
| Collaborator Contribution | Application of decision making tools to microbiological data from drinking water systems. |
| Impact | One publication submitted: https://doi.org/10.3390/w12051247 |
| Start Year | 2019 |
| Description | Continued collaboration with ARM (Christopher Howe) |
| Organisation | Arm Limited |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Analysis of current generation from algal biofilms. |
| Collaborator Contribution | Application of current generation from algal biofilms. |
| Impact | None to date. |
| Start Year | 2020 |
| Description | Continued collaboration with ARM (Christopher Howe) |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Analysis of current generation from algal biofilms. |
| Collaborator Contribution | Application of current generation from algal biofilms. |
| Impact | None to date. |
| Start Year | 2020 |
| Description | Controlling bacterial aggregation |
| Organisation | Fujifilm |
| Department | Fujifilm Diosynth Biotechnologies, UK |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We have made an intellectual contribution to the project and contributed a new experimental system for further investigation and potential exploitation. |
| Collaborator Contribution | The collaborative team have brought intellectual and commercial expertise to the project, and have also linked us up to a wider collaborative group. |
| Impact | This is an interdisciplinary project combining microbiology and molecular biology expertise with insights from soft matter physics and colloidal aggregation/self-assembly. |